


 Cite this: *RSC Adv.*, 2023, **13**, 4376

Copper(II) and silver(I) complexes with dimethyl 6-(pyrazine-2-yl)pyridine-3,4-dicarboxylate (py-2pz): the influence of the metal ion on the antimicrobial potential of the complex†

 Tina P. Andrejević, ^a Ivana Aleksic, ^b Jakob Kljun, ^c Marta Počkaj, ^c Matija Zlatar, ^d Sandra Vojnovic, ^b Jasmina Nikodinovic-Runic, ^b Iztok Turel, ^{*c} Miloš I. Djuran ^{*e} and Biljana Đ. Glišić ^{*a}

Dimethyl 6-(pyrazine-2-yl)pyridine-3,4-dicarboxylate (py-2pz) was used as a ligand for the synthesis of new copper(II) and silver(I) complexes, $[\text{CuCl}_2(\text{py-2pz})_2]_2$ (**1**), $[\text{Cu}(\text{CF}_3\text{SO}_3)(\text{H}_2\text{O})(\text{py-2pz})_2]\text{CF}_3\text{SO}_3 \cdot 2\text{H}_2\text{O}$ (**2**), $[\text{Ag}(\text{py-2pz})_2]\text{PF}_6$ (**3**) and $\{[\text{Ag}(\text{NO}_3)(\text{py-2pz})] \cdot 0.5\text{H}_2\text{O}\}_n$ (**4**). The complexes were characterized by spectroscopic and electrochemical methods, while their structures were determined by single crystal X-ray diffraction analysis. The X-ray analysis revealed the bidentate coordination mode of py-2pz to the corresponding metal ion *via* its pyridine and pyrazine nitrogen atoms in all complexes, while in polynuclear complex **4**, the heterocyclic pyrazine ring of one py-2pz additionally behaves as a bridging ligand between two Ag(I) ions. DFT calculations were performed to elucidate the structures of the investigated complexes in solution. The antimicrobial potential of the complexes **1–4** was evaluated against two bacterial (*Pseudomonas aeruginosa* and *Staphylococcus aureus*) and two *Candida* (*C. albicans* and *C. parapsilosis*) species. Silver(I) complexes **3** and **4** have shown good antibacterial and antifungal properties with minimal inhibitory concentration (MIC) values ranging from 4.9 to 39.0 μM (3.9–31.2 $\mu\text{g mL}^{-1}$). All complexes inhibited the filamentation of *C. albicans* and hyphae formation, while silver(I) complexes **3** and **4** had also the ability to inhibit the biofilm formation process of this fungus. The binding affinity of the complexes **1–4** with calf thymus DNA (ct-DNA) and bovine serum albumin (BSA) was studied by fluorescence emission spectroscopy to clarify the mode of their antimicrobial activity. Catechol oxidase biomimetic catalytic activity of copper(II) complexes **1** and **2** was additionally investigated by using 3,5-di-*tert*-butylcatechol (3,5-DTBC) and *o*-aminophenol (OAP) as substrates.

 Received 21st November 2022
 Accepted 19th January 2023

DOI: 10.1039/d2ra07401j

rsc.li/rsc-advances

Introduction

Antimicrobial resistance to the currently used antimicrobials has become a global problem, which significantly influences the ability of humans to prevent and treat an enormously increasing

number of bacterial and fungal infections and affects the success of cancer chemotherapy.¹ Infections that are caused by multidrug resistant pathogens are associated with longer hospital stays and worse clinical outcomes, such as morbidity and mortality in the infected patients and increased costs on the healthcare system.² In the Review on Antimicrobial Resistance, commissioned by the UK Government, it is estimated that antimicrobial resistance will lead to the death of 10 million people per year by 2050.³ Although this report has been criticized regarding the estimated quantification of morbidity and mortality,⁴ there is no doubt that the spread of antimicrobial resistance is an urgent concern, which requires a global and coordinated action plan, including the development of new antimicrobials with different and more effective mechanisms of action.^{5,6}

A major problem in the field of development of new antimicrobial agents is the fact that approximately 25% of the compounds currently in clinical trials are entirely new structural classes, while the remaining 75% are derivatives of the

^aDepartment of Chemistry, Faculty of Science, University of Kragujevac, R. Domanovića 12, 34000 Kragujevac, Serbia. E-mail: biljana.glisic@pmf.kg.ac.rs

^bInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11042 Belgrade, Serbia

^cFaculty of Chemistry and Chemical Technology, University of Ljubljana, Večna Pot 113, Ljubljana, SI-1000, Slovenia. E-mail: Iztok.Turel@jkk.uni-lj.si

^dDepartment of Chemistry, University of Belgrade-Institute of Chemistry, Technology and Metallurgy, Njegoševa 12, 11000 Belgrade, Serbia

^eSerbian Academy of Sciences and Arts, Knez Mihailova 35, 11000 Belgrade, Serbia. E-mail: milos.djuran@pmf.kg.ac.rs

† Electronic supplementary information (ESI) available: ¹H NMR spectra for py-2pz, **3** and **4**, Fig. S1–S6, Scheme S1, Tables S1–S3 and Cartesian coordinates of all DFT optimized structures. CCDC 2220146–2220150. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d2ra07401j>



already used drugs and represent a short-term solution of the problem.⁷ Moreover, all these compounds in both preclinical and clinical development are purely organic and have simple one- or two-dimensional shapes.⁸ On the contrary, metal complexes can adopt different geometries and generally possess three-dimensional shape, which can contribute to their improved clinical success rates, because molecular shape is one of the most important factors in molecular recognition by a biomolecule.^{9–14} In addition, metal complexes exert different modes of action, including ligand exchange or release, formation of reactive oxygen species (ROS), redox activation and catalytic generation of toxic species, which are difficult or even impossible to be achieved with organic compounds alone.^{15,16} Recently, a comprehensive overview of the developments in the design of metal complexes with antifungal activity have been provided by Gasser *et al.*,¹⁷ highlighting the combination of different metal ions with antifungally active organic molecules, leading to the increased bioavailability, uptake and efficacy of an antifungal agent. This concept can be also successfully used for the development of novel agents for the treatment of cancer and bacterial and parasitic infections.¹⁸ Moreover, Frei *et al.* have assessed the antibacterial and antifungal activity of 906 metal-containing compounds and found an impressive success rate in comparison to purely organic compounds, confirming that the combination of an extended arsenal of potential modes of action with a three-dimensional shape makes them potential antimicrobial drug candidates with some crucial advantages.⁸ It is important to mention that a plethora of metal-based drugs have been studied also as anticancer and antiparasitic agents, antivirals, as adjuvants to elicit an immune response and for many other indications; nevertheless, only a few of them have been successfully introduced into the clinic.^{19,20} Most of the investigated metal complexes act as prodrugs, which can be transformed into the active species either by ligand exchange or redox reactions, and are likely to be multi-targeting in its action.¹⁹


In the last few years, the antimicrobial activity of different copper(II) complexes has been extensively investigated with some promising results.^{1,21–24} For instance, a few copper(II) complexes with 2-acetylpyridine-*N*-substituted thiosemicarbazonates have shown significant antimicrobial potential against methicillin resistant *Staphylococcus aureus* (MRSA), *Klebsiella pneumoniae* and *Candida albicans*, which is comparable to or even better than that of the gentamicin and amphotericin B, used as reference compounds.²¹ A good antibacterial activity against a range of Gram-negative (*Salmonella typhimurium*, *Pseudomonas aeruginosa*, *Escherichia coli* and *K. pneumoniae*) and Gram-positive (MRSA and *Staphylococcus aureus*) bacteria was also shown by copper(II) complexes with *N,N'*-diarylformamidine dithiocarbamate ligands, surpassing in many cases the activity of antibiotic ciprofloxacin.²² Moreover, two copper(II) complexes, [Cu(gluc)(hpb)(H₂O)]gluc and [Cu(gluc)(hpb)(H₂O)]gluc (hpb is 2-(2'-pyridyl)benzimidazole, hpb is 5-chloro-2-(2'-pyridyl)benzimidazole, gluc is D-gluconic acid), have shown good inhibitory activity against three Gram-positive bacteria (*S. aureus*, *Bacillus subtilis*, *Listeria monocytogenes*) and one Gram-negative bacterium (*E. coli*), as well as

good cytotoxic activity against the tested cancer cell lines.²³ On the other hand, no antibacterial effect was observed for five copper(II) complexes with pyridine-4,5-dicarboxylate esters, while two of them, namely [Cu(NO₃)₂(py-2metz)(H₂O)] and [CuCl₂(py-2metz)]_n (py-2metz is dimethyl 2-(4-methylthiazol-2-yl)pyridine-4,5-dicarboxylate), have shown a moderate antifungal activity with a minimal inhibitory concentration (MIC) of 31.25 μg mL⁻¹ against *C. albicans*.²⁴ Similarly, none of the five copper(II) complexes with aromatic nitrogen-containing heterocycles (N-heterocycles), *e.g.* pyrimidine, pyrazine, quinoxaline and phthalazine, manifested significant antimicrobial activity against the investigated bacterial and *Candida* strains.²⁵ Nevertheless, these complexes were able to inhibit bacterial quorum sensing (QS) and, reducing virulence without a pronounced effect on the bacterial growth, they can offer a lower risk for resistance development.²⁵

Following the use of silver(I) sulfadiazine as a broad-spectrum topical antibiotic for some burn wounds,²⁶ different classes of silver(I) complexes have attracted attention for their antimicrobial properties, such as those with N-heterocyclic carbenes (NHCs) and N-heterocycles as ligands.^{27–30} Even though silver(I) complexes have shown significant growth inhibitory effects against Gram-positive and Gram-negative bacteria and fungi, their exact mode of action remained not well understood. Nevertheless, the most reported one includes a slow release of the active Ag(I) ions, which further react with the thiol or other key functional groups of proteins and enzymes,^{31–33} leading to the denaturation of proteins and the impairing of the membrane function.^{34,35} Besides that, Ag(I) ions can produce ROS, which target lipids, nucleic acids and proteins, causing their malfunction.³⁶ Moreover, treatment of bacteria with silver(I) ions was found to induce the condensation of DNA molecules in the cytoplasm, resulting in the loss of DNA replication ability and, consequently, in the death of bacteria.^{33,34} Although the mechanism of action of silver(I) complexes is not well understood, it has been proposed that the antimicrobial activity of these complexes is mainly connected to their solubility, stability, lipophilicity, redox ability, and rate of Ag(I) ions release.³³ All these factors are directed by the choice of suitable ligands, and they are fundamental for maintaining the bioavailability of complex during an extended period, thus preventing reinfection or resistance development.

Based on the all above reasons, in the present study, new copper(II) and silver(I) complexes, namely [CuCl₂(py-2pz)]₂ (1), [Cu(CF₃SO₃)(H₂O)(py-2pz)₂](CF₃SO₃·2H₂O) (2), [Ag(py-2pz)₂]PF₆ (3) and {[Ag(NO₃)(py-2pz)]·0.5H₂O}_n (4), were synthesized with dimethyl 6-(pyrazine-2-yl)pyridine-3,4-dicarboxylate (py-2pz) as ligand (Scheme 1). Two different metal ions were chosen to check how they can influence on the antimicrobial activity of the resulted metal complex. Moreover, py-2pz was chosen as a versatile ligand which can behave both as bridging and chelating bidentate ligand (Scheme 1). Structurally similar ligands such as derivatives of different pyridine-4,5-dicarboxylate esters, dimethyl 2-(thiazol-2-yl)pyridine-4,5-dicarboxylate (py-2tz), dimethyl 2-(4-methylthiazol-2-yl)pyridine-4,5-dicarboxylate (py-2metz) and dimethyl 2,2'-bipyridine-4,5-dicarboxylate (py-2py), were previously used for





Scheme 1 Schematic presentation of the synthesis of $[\text{CuCl}_2(\text{py-2pz})_2]$ (1), $[\text{Cu}(\text{CF}_3\text{SO}_3)(\text{H}_2\text{O})(\text{py-2pz})_2]\text{CF}_3\text{SO}_3 \cdot 2\text{H}_2\text{O}$ (2), $[\text{Ag}(\text{py-2pz})_2]\text{PF}_6$ (3) and $[\text{Ag}(\text{NO}_3)(\text{py-2pz})] \cdot 0.5\text{H}_2\text{O}$ (4). Note that numbering scheme of atoms in py-2pz does not match the one applied in the X-ray study of the complexes. All reactions were performed by mixing the reactants in 1:1 molar ratio in ethanol at room temperature.

the synthesis of silver(I) complexes, which have shown the significant activity against cow mastitis associated pathogens,³⁷ of ruthenium(II) complexes as inhibitors of aldo-keto reductases³⁸ and 15-lipoxygenase-1,³⁹ and of the abovementioned copper(II) complexes,²⁴ as well as antifungal zinc(II) complex.⁴⁰ The antimicrobial activity of the synthesized complexes 1–4 were evaluated against two bacterial (*P. aeruginosa* and *S. aureus*) and two *Candida* (*C. albicans* and *C. parapsilosis*) species, as well as their toxicity on the human normal fibroblast cell line (MRC-5). With the aim to obtain a more detailed information on the antifungal potential of the complexes, their inhibitory activity on *C. albicans* filamentation and biofilm formation was investigated. The DNA/BSA binding properties of the complexes were investigated by fluorescence emission spectroscopic method, while oxidase catalytic activity of copper(II) complexes 1 and 2 was studied by 3,5-di-*tert*-butylcatechol (3,5-DTBC) and *o*-aminophenol (OAP) as substrates.

Results and discussion

Synthesis and structural characterization of complexes 1–4

Dimethyl 6-(pyrazine-2-yl)pyridine-3,4-dicarboxylate (py-2pz) (Scheme 1), which contains two aromatic nitrogen-containing

heterocyclic rings, pyridine and pyrazine, is potentially good chelating ligand for different metal ions. In order to investigate the coordination mode and binding ability of py-2pz ligand to the metal ions, in the present study this compound has been prepared by following the previously reported procedure⁴¹ and its reactions with different copper(II) and silver(I) salts have been investigated.

Copper(II) and silver(I) complexes, $[\text{CuCl}_2(\text{py-2pz})_2]$ (1), $[\text{Cu}(\text{CF}_3\text{SO}_3)(\text{H}_2\text{O})(\text{py-2pz})_2]\text{CF}_3\text{SO}_3 \cdot 2\text{H}_2\text{O}$ (2), $[\text{Ag}(\text{py-2pz})_2]\text{PF}_6$ (3) and $[\text{Ag}(\text{NO}_3)(\text{py-2pz})] \cdot 0.5\text{H}_2\text{O}$ (4) were obtained in a good yield in ethanol *via* the aerobic reaction of py-2pz ligand with an equimolar amount of the corresponding CuX_2 ($\text{X} = \text{Cl}^-$ (1) and CF_3SO_3^- (2)) or AgX ($\text{X} = \text{PF}_6^-$ (3) and NO_3^- (4)) salt at room temperature (Scheme 1). They were characterized by elemental analysis, molar conductivity measurement, spectroscopic (IR, UV-Vis, ^1H NMR for 3 and 4) and electrochemical (cyclic voltammetry) methods, while their crystal structures were determined by single crystal X-ray crystallography. DFT calculations were performed to elucidate the structures of the synthesized complexes 1–4 in solution.

Solid state studies

Crystal structures of 1–4. Complex 1 crystallizes as a dichlorido bridged dimer, structurally similar to the previously reported analogue $[\text{CuCl}_2(\text{py-2tz})_2]$ containing the thiazole-substituted pyridine-4,5-dicarboxylate ester as a ligand.²⁴ The square pyramidal geometry of the complex is only slightly distorted with the τ_5 value⁴² of 0.10 ($\tau_5 = 0$ and 1 for ideal square pyramidal and trigonal bipyramidal geometry, respectively). The Cu(II) ion sits almost in the basal plane of the square pyramid (distance between the N_2Cl_2 plane of 0.139 Å). The use of the copper(II) triflate in the synthesis results in a octahedral complex 2 with metal-to-py-2pz ligand molar ratio 1:2 and with one coordinated triflate ligand and one co-crystallized as counter-anion (Fig. 1). The octahedral coordination sphere is completed with a coordinated water molecule which is part of a hydrogen bond network consisting of two additional solvate water molecules. Electronic effects result in slight elongation of the axial Cu–N bond by approximately 0.25 Å and a significant elongation of the Cu–O_{triflate} bond (2.39 Å; selected bond lengths and angles are summarized in the caption of Fig. 1). The triflate anion is highly disordered and we were not able to appropriately model the fragment to completely fit the residual electron density. Thus, a second structural model was proposed, using the Solvent mask function within Olex2-1.3 (ref. 43) to remove the residual electron density and calculate the void. The integrated electron density corresponds to 78 electrons within a 170 Å³. The electron count corresponds to the triflate ion; however, the void is indeed too spacious allowing for a highly disordered structure (21.25 Å³ per non-hydrogen atom). For more details see ESI.†

In the case of silver(I) complexes, the use of silver(I) hexafluorophosphate results in a four-coordinated complex 3 with metal-to-ligand molar ratio 1:2, having an intermediate geometry between square planar and tetrahedral with τ_4/τ'_4 values⁴⁴ of 0.51/0.47. τ_4 value is 0 and 1 for ideal square planar






Fig. 1 Crystal structures of complexes 1–4. The ellipsoids are presented at 30% probability level. Hydrogen atoms except those bound to heteroatoms and PF_6^- counter-anion and crystalline water molecule in 3 and 4, respectively, are omitted for better clarity. Selected bond lengths: (1) Cu1–N1A 2.038(3); Cu1–N7A 2.032(3); Cu1–Cl1 2.2261(9); Cu1–Cl1 2.2261(9); Cu1–Cl2_(inplane) 2.2675(8); Cu1–Cl2_(apical) 2.6639(7); (2) Cu1–N1A 1.999(4); Cu1–N7A 2.018(5); Cu1–N1B 2.022(4); Cu1–N7B 2.262(6); Cu1–O1D 2.388(5); Cu1–O1C 1.981(4); (3) Ag1–N1A 2.307(2); Ag1–N7A 2.342(2); Ag1–N1B 2.260(2); Ag1–N7B 2.484(2); (4) Ag1–N1A 2.392(3); Ag1–N7A 2.303(2); Ag1–N10A 2.239(2); Ag1–O1B 2.397(3).

and tetrahedral geometry, respectively.⁴⁴ Reaction of py-2pz with silver(I) nitrate leads to the formation of a four-coordinated polymeric species 4, however in contrast to the previously reported structures of pyridine-4,5-dicarboxylate ester ligands bearing a second pyridyl/thiazolyl/2-methylthiazolyl ring,³⁷ the nitrate in the complex 4 acts as terminal monodentate ligand and the polymeric species is bridged by the binding of a second silver(I) ion to the N10 nitrogen atom of the pyrazine ring. The geometry in this case is a slightly distorted tetrahedron with τ_4/τ'_4 values⁴⁴ of 0.76/0.73.

IR spectra. The IR spectra of the complexes 1–4, recorded in the wavenumber range of 4000–450 cm^{-1} , are in accordance with the determined X-ray structures. They show the bands, which can be attributed to the vibrations of the coordinated py-2pz ligand (see Experimental section for the IR bands assignments). Additionally, in the IR spectrum of 2, which contains triflate both monodentate coordinated and a counter-anion, a few strong absorptions in the 1300–1000 cm^{-1} region can be observed.²⁵ Besides that, a broad absorption at $\sim 3475 \text{ cm}^{-1}$ in this spectrum is attributed to the stretching vibration of O–H bond and is in accordance with the presence of a coordinated and crystalline water molecule in complex 2.⁴⁵ In the case of silver(I) complex 3, which contains PF_6^- incorporated in the crystal lattice as a counter-anion, a very strong band at 839 cm^{-1} was detected, which is due to the stretching vibrations of the

P–F bond.^{46,47} Regarding the IR spectrum of 4, the band corresponding to the asymmetric stretching modes of nitrate is split into two bands (at 1384 and 1368 cm^{-1}), with a small separation ($\Delta\nu = 16 \text{ cm}^{-1}$), being in accordance with a monodentate coordination of this anion to the Ag(I).⁴⁸

Solution studies

¹H NMR spectra for silver(I) complexes 3 and 4 were recorded in DMSO- d_6 with the aim to confirm the bidentate coordination of the py-2pz to the Ag(I) ion in these complexes (¹H NMR spectra are given in ESI†). For this purpose, the ¹H NMR spectra of the silver(I) complexes were compared with that of the uncoordinated py-2pz ligand (ESI†). In the spectra of complexes, the number of signals is the same as that of py-2pz, confirming its bidentate coordination to the Ag(I) ion. However, the proton resonances in the spectra of complexes are almost at the same chemical shifts compared to those of the ligand, which is an expected spectroscopic behavior of the silver(I) complexes in DMSO- d_6 and can be a consequence of the fast ligand exchange on the NMR timescale.⁴⁹

The UV-Vis spectra of complexes 1–4 were recorded in DMSO at room temperature. In the visible region of the spectra of copper(II) complexes 1 and 2, a low intensity band ($\epsilon = 102.0$ and 43.8 $\text{M}^{-1} \text{ cm}^{-1}$) assigned to d–d transition appears at 875.0 and 805.0 nm, is observed (Fig. S1†).⁵⁰ On the other hand, silver(I)



complexes **3** and **4** exhibit the absorbance peak at 296.0 nm, which is caused by the intraligand charge transfer transitions.⁵¹ The absorbance peaks for both complexes show a blue shift compared to that for the free py-2pz ligand ($\lambda = 326.0$ nm) (Fig. S2†).

Further, the UV-Vis spectra of the complexes were recorded in the presence of DMSO (a solvent used for the preparation of stock solutions for the biological experiments) and in DMSO/PBS solution (PBS is phosphate buffered saline; Fig. S3†), immediately after their dissolution, as well as after 48 h. Since no significant changes (shift of the absorbance maximum or the appearance of new bands) were observed in the UV-Vis spectra during time of measurements, it can be proposed that the py-2pz ligand remains coordinated to the corresponding metal ion in solution.

The molar conductivity measurements undoubtedly confirm the constitution of copper(II) complexes **1** and **2**, and are in accordance with the fact that **1** behaves as nonelectrolyte, while **2** is 1 : 1 type of electrolyte.⁵² On the other hand, the values of molar conductivity for **3** and **4** are not conclusive and only suggest the presence of ionic species in solution, which is expected for **3**.




Fig. 2 Cyclic voltammograms of the copper(II) (**1** and **2**; A) and silver(I) (**3** and **4**; B) complexes at GC electrode in DMSO ($c = 1 \times 10^{-3}$ M) and 0.1 M TBAHP as a supporting electrolyte with a scan rate of 50 mV s^{-1} .

The electrochemical behavior of metal complexes is of great importance for a better understanding of their redox stability, as well as biological activity and mode of interaction with biologically important biomolecules.^{53,54} The cyclic voltammograms of complexes **1–4** and py-2pz were recorded in DMSO at glassy carbon (GC) electrode in DMSO and 0.1 M tetrabutylammoniumhexafluorophosphate (TBAHP) as a supporting electrolyte, under following conditions, $E_{\text{begin}} = -2.0$ V and $E_{\text{end}} = 2.0$ V (Fig. 2 and S4†). It is important to mention that py-2pz ligand is redox inactive in the applied voltage range (Fig. S4†). As can be seen from Fig. 2A, in the cyclic voltammogram of complex **1**, only one reduction peak at -0.27 V is observed, which can be attributed to the $\text{Cu(II)} \rightarrow \text{Cu(I)}$ process, while the complex **2** showed two reduction peaks, at -0.05 and -0.89 V for $\text{Cu(II)} \rightarrow \text{Cu(I)}$ and $\text{Cu(I)} \rightarrow \text{Cu(0)}$ reduction processes, respectively, which were assigned in accordance with the literature data for the previously reported copper(II) complexes, including those with the structurally similar pyridine-4,5-dicarboxylate esters.^{24,55,56} The presence of only one reduction peak in the voltammogram of complex **1** can be the consequence of its higher redox stability compared to that of **2**.

On the other hand, silver(I) complexes **3** and **4** in anodic direction show one oxidation peak I_a corresponding to the $\text{Ag(I)} \rightarrow \text{Ag(II)}$ process (Fig. 2B).^{37,57–59} When the cyclic voltammogram was recorded in the cathodic direction, two reduction peaks $I_{c,1}$ and $I_{c,2}$ were observed, which can be attributed to the $\text{Ag(II)} \rightarrow \text{Ag(I)}$ and $\text{Ag(I)} \rightarrow \text{Ag(0)}$ processes, respectively (Fig. 2B), in accordance with the other silver(I) complexes which electrochemical behavior was previously reported.^{37,57–59}

Computational results

DFT calculations were performed to clarify the structures of complexes **1–4** in DMSO solution. For this purpose, we relied on the thermodynamics of possible reactions starting from the X-ray determined structures.⁶⁰ Free energy changes, $\Delta_r G$ (298 K), for the formation of probable coordination structures were investigated (Table 1). $\Delta_r G$ (298 K) was calculated based on the difference in Gibbs free energies of products and reactants at ZORA-M06-2X/TZP-COSMO(DMSO)//ZORA-BP86-D4/TZP-COSMO(DMSO) level of theory.

For complex **1**, the formation of tetra-coordinate, mononuclear $[\text{CuCl}_2(\text{py-2pz})_2]$ species (Fig. 3) is thermodynamically favoured. Two Cu(II) centers in **1** are very weakly ferromagnetically coupled, with the exchange constant $J = 0.3 \text{ cm}^{-1}$ calculated in broken-symmetry formalism at ZORA-M06-2X/TZP//X-

Table 1 Gibbs free energy changes ($\Delta_r G$ in kcal mol^{-1} at $T = 29$ K) calculated at ZORA-M06-2X/TZP-COSMO(DMSO)//ZORA-BP86-D4/TZP-COSMO(DMSO) level of theory for the formation of different copper(II) and silver(I) complexes, based on the crystal structures

Reaction	$\Delta_r G$ (298 K)
$[\text{CuCl}_2(\text{py-2pz})_2]_2 (\mathbf{1}) \rightleftharpoons 2 [\text{CuCl}_2(\text{py-2pz})]$	-3.75
$[\text{Cu}(\text{CF}_3\text{SO}_3)(\text{H}_2\text{O})(\text{py-2pz})_2]_2^+ (\mathbf{2}) \rightleftharpoons [\text{Cu}(\text{H}_2\text{O})(\text{py-2pz})_2]^{2+} + \text{CF}_3\text{SO}_3^-$	-2.01
$[\text{Cu}(\text{CF}_3\text{SO}_3)(\text{H}_2\text{O})(\text{py-2pz})_2]_2^+ (\mathbf{2}) \rightleftharpoons [\text{Cu}(\text{CF}_3\text{SO}_3)(\text{py-2pz})_2]^+ + \text{H}_2\text{O}$	-3.58
$[\text{Cu}(\text{CF}_3\text{SO}_3)(\text{H}_2\text{O})(\text{py-2pz})_2]_2^+ (\mathbf{2}) \rightleftharpoons [\text{Cu}(\text{py-2pz})_2]^{2+} + \text{CF}_3\text{SO}_3^- + \text{H}_2\text{O}$	-4.86
$[\text{Ag}(\text{py-2pz-}N,N')_2]^+ (\mathbf{3}) \rightleftharpoons [\text{Ag}(\text{py-2pz-}N,N')(\text{py-2pz-}N)]^+$	+11.26
$[\text{Ag}(\text{NO}_3)(\text{py-2pz-}N,N')(\text{py-2pz-}N)] (\mathbf{4}) \rightleftharpoons [\text{Ag}(\text{py-2pz-}N,N')(\text{py-2pz-}N)]^+ + \text{NO}_3^-$	+4.04






Fig. 3 The structures of $[\text{CuCl}_2(\text{py-2pz})]$ (left), $[\text{Cu}(\text{py-2pz})_2]^{2+}$ (middle) and $[\text{Ag}(\text{NO}_3)(\text{py-2pz-}N,N')(\text{py-2pz-}N)]$ (right) optimized at the ZORA-BP86-D4/TZP-COSMO(DMSO) level of theory.

ray level of theory. Unpaired electrons are in the local $d_{x^2-y^2}$ orbital, and the spin density is mainly located in the equatorial plane of the subunits that are parallelly displaced. Delocalization of the spin density is towards directly coordinated equatorial donor atoms (Fig. S5[†]).

In the case of complex 2, dissociation of weakly coordinated CF_3SO_3^- and of monodentate aqua ligand were considered. Thermodynamically the formation of tetra-coordinate $[\text{Cu}(\text{py-2pz})_2]^{2+}$ is preferred (Fig. 3). For polymeric structure 4, a model complex $[\text{Ag}(\text{NO}_3)(\text{py-2pz-}N,N')(\text{py-2pz-}N)]$ was considered, built from the corresponding X-ray structure. In this structure, one py-2pz ligand is bidentate (py-2pz- N,N'), while the other is monodentate (py-2pz- N) (Fig. 3). Dissociation of monodentate NO_3^- is disadvantageous according to positive $\Delta_r G$. In complex 3, both py-2pz ligands are bidentately coordinated to the Ag(I) center. Structure 3 is the most stable, with two py-2pz ligands coordinated to Ag(I) center, ignoring possible polymerization.

Biological studies

Antimicrobial activity and *in vitro* toxicity assessment. Given the reported antimicrobial properties shown by various copper(II) and silver(I) complexes,³³ the activity of the newly synthesized complexes 1–4, along with py-2pz ligand used for their synthesis, were evaluated against one Gram-positive (*S. aureus*) and one Gram-negative bacteria (*P. aeruginosa*), and two *Candida* species (*C. albicans* and *C. parapsilosis*), and the obtained results were given as MIC values (μM and $\mu\text{g mL}^{-1}$) in Table 2. Silver(I) sulfadiazine (AgSD) as the most widely used antimicrobial agent based on the silver(I) is used as a positive

control. The antimicrobial activity of CuX_2 and AgX salts against different bacterial and fungal strains was previously investigated.^{45,61} Although AgX salts have manifested remarkable antimicrobial activity, their use has been limited due to the precipitation of Ag(I) ion in the form of AgCl under physiological conditions, preventing its action in the infected cells.⁶² On the other hand, no significant activity on the investigated bacterial strain was exerted by CuX_2 salts.⁴⁵

As can be seen from Table 2, silver(I) complexes 3 and 4 showed a good antifungal activity on both tested *Candida* strains (*C. albicans* and *C. parapsilosis*) with MIC values of 4.9 and 8.6 μM (3.9 $\mu\text{g mL}^{-1}$), respectively, while no significant anti-*Candida* activity was observed for copper(II) complexes 1 and 2. Both silver(I) complexes 3 and 4 are more active against *C. albicans* than the clinically used AgSD complex (Table 2). Regarding antibacterial activity, polynuclear silver(I) complex 4 with coordinated py-2pz and nitrate was the most active, with MIC value of 8.6 μM (3.9 $\mu\text{g mL}^{-1}$) against *P. aeruginosa* PAO1, while slightly reduced activity was noted for 3 against the same strain with MIC being 19.5 μM (15.6 $\mu\text{g mL}^{-1}$); this complex is mononuclear and contains two bidentately coordinated py-2pz ligands). Moreover, both investigated copper(II) complexes 1 and 2 show only a moderate activity against *P. aeruginosa* PAO1. The activity of the complexes against this microbial species is of particular interest, since it is a human pathogen, responsible for severe infections, including those associated with cystic fibrosis, burn wounds and the use of catheters, and is a major cause of nosocomial infections.^{63–65} The corresponding py-2pz ligand did not affect the microbial growth at 1830 μM (500 $\mu\text{g mL}^{-1}$), indicating that the observed activity of the silver(I)

Table 2 Antimicrobial activity of the investigated complexes, copper(II) (1 and 2) and silver(I) (3 and 4), and py-2pz ligand (MIC, μM ($\mu\text{g mL}^{-1}$)) in comparison to their antiproliferative effect on normal human fibroblast cell line MRC-5 (IC_{50} , μM ($\mu\text{g mL}^{-1}$)).^a The MIC and IC_{50} values of silver(I) sulfadiazine (AgSD) were given for comparative purposes

Microorganism/cell	Compound/MIC and IC_{50} , μM ($\mu\text{g mL}^{-1}$)					
	1	2	3	4	py-2pz	AgSD
<i>S. aureus</i> ATCC 25923	>613.2 (>500)	>519.6 (>500)	39.0 (31.2)	34.5 (15.6)	>1830 (>500)	75 (26.8)
<i>P. aeruginosa</i> PAO1	153.3 (125)	259.8 (250)	19.5 (15.6)	8.6 (3.9)	>1830 (>500)	25 (8.9)
<i>C. albicans</i> ATCC 10231	613.2 (500)	>519.6 (>500)	4.9 (3.9)	8.6 (3.9)	>1830 (>500)	10 (3.6)
<i>C. parapsilosis</i> ATCC 22019	613.2 (500)	519.6 (500)	4.9 (3.9)	8.6 (3.9)	>1830 (>500)	2.5 (0.89)
MRC-5 cells	85.8 (70)	129.9 (125)	31.3 (25)	16.6 (7.5)	439.2 (120)	10 (3.6)

^a Results are given as mean of three independent measurements with standard error being between 1–3%.



complexes is due to the presence of Ag(I) ions. As it was mentioned in the Introduction, the antimicrobial activity of silver(I) complexes is connected to their ability to release free Ag(I) ions, which show the activity through different pathways.³³ In general, the antimicrobial activity of silver(I) complexes 3 and 4 is similar to that previously reported for those with pyridine-4,5-dicarboxylate esters,³⁷ which are structural analogues of py-2pz. Moreover, silver(I) complexes with pyridinecarboxylates (picolinate, nicotinate and dipicolinate) have shown a significant activity against *C. parapsilosis* (MIC = 5 μM), with fungistatic effect, while the antibacterial activity against *S. aureus* was higher (MIC = 10 μM)⁶⁶ in comparison to 3 and 4. A similar antimicrobial activity against *C. parapsilosis* and *S. aureus* was also shown by polymeric silver(I) complexes with pyridine-3,5-dicarboxylate⁶⁷ and pyridine-2-sulfonate.⁶⁸

Regarding previously reported copper(II) complexes, those with pyridine-4,5-dicarboxylate esters did not affect bacterial growth under the tested conditions, and only moderate antifungal activity against *C. albicans* ATCC 10231 was noted.²⁴ On the other hand, copper(II) complexes with 2-hydroxypyridine, 2-aminopyridine and pyridine-2-carboxylic acid inhibited the growth of *B. subtilis* and partially inhibited the growth of *C. albicans* ATCC 90028,⁶⁹ while [Cu(2,2'-bipy)Cl₂(thiouracil)] (2,2'-bipy is 2,2'-bipyridine) has shown fungicidal and fungistatic activities against 21 clinical isolates of *Candida* spp.⁷⁰

Antiproliferative activity of both copper(II) and silver(I) complexes have been previously investigated on different human cells.^{71,72} In the present study, with the aim to check the therapeutic potential of complexes 1–4, their antiproliferative activity on the human normal fibroblast cell line (MRC-5) was tested. The obtained IC₅₀ values (μM and $\mu\text{g mL}^{-1}$; IC₅₀ is defined as the concentration inhibiting 50% of cell growth after 48 h treatment with the tested compounds) are given in Table 2. From the presented data, it can be concluded that the silver(I) complexes 3 and 4 have the positive values of selectivity indices (SI; the ratio between IC₅₀ and MIC values), with the best therapeutic profile (SI = 6.4) in respect to MRC-5 observed for 3 against both *Candida* spp. (Table 2). Moreover, the complexes 3 and 4 are 3.1 and 1.7-fold less toxic against MRC-5, respectively, than AgSD.

The investigated copper(II) complexes 1 and 2 also show effects on the viability of the MRC-5 cells, whereby complex 1 appeared to be more cytotoxic (Table 2). However, the cytotoxic activity of py-2pz ligand against MRC-5 cells was 120 μM , suggesting that some of the effects observed for the complexes are due to this ligand.⁴⁵ Similarly, IC₅₀ values in the range 24.0–289.0 μM were previously reported for copper(II) complexes with aromatic N-heterocycles on the same cell line.²⁵ Contrary to this, copper(II) complexes of the Casiopeínas® family, [Cu(L-N,N')(X-N,O)]NO₃ and [Cu(L-N,N')(Y-O,O')]NO₃, L is 2,2'-bipyridine, 1,10-phenanthroline or their substituted derivatives, X is an essential amino acid or peptide and Y is acetylacetonate or salicylaldehyde,^{73–77} and copper(II) complexes with 2,2':6',2''-terpyridine (terpy) or its 4'-substituted derivatives^{78–82} have shown remarkable antiproliferative activity in several cell lines.

Inhibition of *C. albicans* ATCC 10231 filamentation and biofilm formation. Morphological transformation from yeast-




Fig. 4 The appearance of *C. albicans* colonies under a stereomicroscope (SMZ143-N2GG, Motic, Germany) after 24 and 72 h of incubation, grown on Spider medium supplemented with 0.5 \times MIC of copper(II) (1 and 2) and silver(I) (3 and 4) complexes, py-2pz and DMSO.

to-hyphae form represents one of the main virulence factors associated with the pathogenesis of *C. albicans* infections.⁸³ Thus, the formation of hyphae is essential for penetration of *C. albicans* to human cells and invasion of tissues during the initial phases of infection.⁸⁴ Recently, different metal complexes, including silver(I) and copper(II) complexes, have been shown to inhibit *C. albicans* cellular differentiation.^{85,86} The effect of copper(II) (1 and 2) and silver(I) (3 and 4) complexes on the *C. albicans* hyphae formation was evaluated on Spider medium.⁸⁷ In the subinhibitory concentrations (0.5 \times MIC), all complexes 1–4, prevented almost completely the formation of hyphae in comparison to DMSO control, while py-2pz did not show a potency to inhibit *C. albicans* filamentous growth on Spider medium (Fig. 4).

Yeast-to-hyphae transition is also the early step in *Candida* biofilm formation.⁸⁴ Biofilms represent the most common mode of fungal growth and have importance in nosocomial infections, due to their high antimicrobial resistance.⁸⁸ Having established that silver(I) complexes 3 and 4 have shown significant anti-*Candida* activity and that they completely inhibit the formation of hyphae, their ability to effect *C. albicans* biofilm formation process was analyzed (Table S1†). When MIC of the complexes was applied, the percentage of the formed *C. albicans* biofilms was 51% and 62% for complexes 3 and 4, respectively. No activity of complex 4 was observed at lower concentrations, while complex 3 had an impact on biofilm formation even at 0.99 μM (0.44 $\mu\text{g mL}^{-1}$).

Anti-quorum sensing potential of complexes 1–4. Quorum sensing (QS) is an intercellular communication process, which regulates the pathogenicity in many bacteria, including *P. aeruginosa*.²⁵ It is considered as one of the most promising targets for anti-virulence therapy.⁸⁹ Inspired by the findings that copper(II) complexes with aromatic N-heterocycles (pyrimidine, pyrazine, quinazoline and phthalazine) and different diamines (1,3-propanediamine, 2,2-dimethyl-1,3-propanediamine and (\pm)-1,3-pentanediamine),⁹⁰ as well as silver nanoparticles (AgNPs),^{91–93} have shown as inhibitors of bacterial QS activity, the effect of complexes 1–4 (100 μg per disc) on bacterial QS was tested using two biosensor strains, *Chromobacterium violaceum* CV026 (violacein producer) and *Serratia marcescens* (prodigiosin producer) (Fig. S6†). No anti-QS activity of copper(II) complexes 1 and 2 on the production of *C. violaceum* CV026 and *S. marcescens* pigments was observed. On the other hand, silver(I) complexes 3 and 4 had a slight antibacterial effect on *C. violaceum* CV026, with clear zones of inhibition of 5 mm.



Interaction with biomolecules

Protein binding study. One of the most abundant serum proteins is serum albumin (SA), and it has an important role in the transport of metal ions and complexes through the bloodstream to cells and tissues.⁹⁴ Considering this, the interaction of serum albumins with a bioactive compound is important in design of novel therapeutic agents since their properties can be changed after binding to SA or novel alternative transportation pathways may be provided.⁹⁵ In the present study, the interaction of copper(II) (1 and 2) and silver(I) (3 and 4) complexes with bovine serum albumin (BSA) was studied by fluorescence emission quenching experiments. BSA is chosen as a model protein because it has a high degree of homology with human serum albumin (HSA).⁹⁶

The emission spectra of BSA were recorded in the absence and presence of an increasing amount of the complexes 1–4, in the wavelength range from 295.0 to 500.0 nm, after excitation of the protein at $\lambda_{\text{ex}} = 290.0$ nm. Fig. 5 illustrates the behavior of BSA solution after the addition of an increasing concentration (0–130 μM) of copper(II) complex 1. As can be seen, BSA shows a very intensive fluorescence at 365.0 nm in the PBS solution (pH = 7.4), which mainly originates from tryptophan, tyrosine, and phenylalanine residues in this biomolecule.⁹⁷ After the addition of complexes 1–4 to BSA solution of a constant concentration (5 μM), a decrease of fluorescence intensity at 365.0 nm was observed, because of their binding to BSA (Fig. 5).

The data calculated by Stern–Volmer and Scatchard equations (Stern–Volmer constants (K_{sv}), quenching rate constants (K_{q}), binding constants (K_{A}) and the number of binding sites per BSA (n)) are presented in Table 3. The K_{sv} values follow the order $1 > 3 > 2 > 4$, indicating that silver(I) complex 4 has a lowest affinity for BSA compared to the remaining three complexes.




Fig. 5 Fluorescence emission spectra of BSA in the absence and presence of an increasing concentration of copper(II) complex 1. The arrow shows the fluorescence intensity changes upon increased concentrations of the complex. Inserted graph: Stern–Volmer plots of F_0/F vs. [complex].

The values of K_{q} constants of the complexes are significantly higher than $2 \times 10^{10} \text{ M}^{-1} \text{ s}^{-1}$, being in accordance with a static quenching mechanism.⁹⁸ The K_{A} values of the complexes are in the range 2.15×10^4 to $6.03 \times 10^6 \text{ M}^{-1}$ and they show the affinity of the complexes to bind to SA for their transport towards the biological targets. However, these constants are much lower than those for the strongest noncovalent interaction ($\sim 10^{15} \text{ M}^{-1}$),⁹⁹ suggesting the reversible binding of the complexes to BSA and their release upon arrival at the target sites. The number of binding sites per BSA molecule suggests the binding of complexes to one site per protein molecule.

Lipophilicity assay. The lipophilicity of a compound can relate to its cellular uptake efficiency, and, hence, it is very important in design of novel biologically active compounds.^{100,101} As a measure of lipophilicity, partition coefficient ($\log P$) between the hydrophobic octanol phase and the hydrophilic water phase shows the ability of a compound to be transported through the cell membrane.¹⁰² The values of $\log P$ for clinically used drugs, including metal-based compounds in the Comprehensive Medicinal Chemistry database are in range from -0.4 to 5.6 .¹⁰³ The presently synthesized copper(II) (1 and 2) and silver(I) (3 and 4) complexes have the values in this ideal lipophilicity range, from 0.86 to 2.28 . Complex 3 has a greater $\log P$ value than the remaining complexes, suggesting its distribution mainly in the octanol phase.

Except $\log P$ value of a potentially new therapeutic agent, its molecular weight should be taken into consideration according to the Lipinski's rule of five.¹⁰⁴ According to this rule, it is highly desirable that the molecular weight of orally bioavailable drugs does not exceed 500 due to their easier uptake. In the case of the presently synthesized complexes, the molecular weight of 1–3 is higher than 500, and approximately 500 for 4. However, this does not limit their potential application in therapeutic purposes since there are many examples of significantly larger molecules that can be efficiently transported into cells.¹⁰⁵ Moreover, it was found that metal-based drugs often do not follow the Lipinski's rule of five and that in the case of these drugs, molecular volume should be considered as an alternative of molecular weight.¹⁹

DNA binding study. Study of DNA interactions of different metal complexes is important for design of novel metal-based therapeutic agents.¹⁰⁶ Metal ions can neutralize the negative charge of DNA, enabling its normal functions, but many other interactions are also possible and can lead to conformational changes or cleavage of this biomolecule.¹⁰⁶ The interaction of copper(II) (1 and 2) and silver(I) (3 and 4) complexes with ct-DNA was investigated by fluorescence emission spectroscopy in

Table 3 Values of the binding constants of copper(II) (1 and 2) and silver(I) (3 and 4) complexes with BSA

Complex	$K_{\text{sv}} (\text{M}^{-1})$	Hypochromism (%)	$K_{\text{q}} (\text{M}^{-1} \text{ s}^{-1})$	$K_{\text{A}} (\text{M}^{-1})$	n
1	$(8.74 \pm 0.13) \times 10^5$	84.4	8.74×10^{13}	6.03×10^6	1.55
2	$(2.28 \pm 0.06) \times 10^5$	84.4	2.28×10^{13}	5.81×10^5	1.17
3	$(5.41 \pm 0.11) \times 10^5$	79.4	5.41×10^{13}	3.08×10^6	1.48
4	$(2.10 \pm 0.02) \times 10^4$	60.5	2.10×10^{12}	2.15×10^4	1.02



a competitive study with ethidium bromide (EthBr), which is a well-known intercalating marker.¹⁰⁷ EthBr intercalates between adjacent base pairs in the DNA double helix, and this process results in the enhancement of DNA fluorescence intensity.¹⁰⁷

The interaction of the complexes 1–4 with ct-DNA was investigated by the addition of increasing amounts of investigated complexes 1–4 (0–190 μM) into the EthBr-ct-DNA adduct solution ($[\text{ct-DNA}]/[\text{EthBr}] = 10$). The behavior of the latter solution in the presence of complexes was monitored through the changes of the fluorescence intensity at $\lambda_{\text{ex}} = 545.0 \text{ nm}$. It is important to note that none of the tested complexes show fluorescence at room temperature in solution or in the presence of DNA at $\lambda_{\text{ex}} = 545.0 \text{ nm}$. The fluorescence emission spectra for EthBr-ct-DNA system in the absence and presence of increasing concentrations of silver(i) complex 4 are shown in Fig. 6.

In all cases, after addition of the investigated complexes, a decrease in fluorescence intensity was observed, indicating their interaction with EthBr-ct-DNA. This decrease can be the consequence of EthBr displacement by the complex, or the binding of a complex to EthBr-ct-DNA system, leading to the formation of a new non-fluorescent adduct.⁹⁸ Since K_A values of the investigated complexes (Table 4) are much lower than that for EthBr ($K_A = 2 \times 10^6 \text{ M}^{-1}$)⁹⁸ and that the percentage of hypochromism is less than 30% (for DNA intercalator lucigenin is 50%),¹⁰⁸ the possible mode of their binding to ct-DNA is non-intercalative (electrostatic). Moreover, the interaction between ct-DNA and 1–4 is a dominantly static quenching process, what can be concluded from the values of K_q constants (Table 4), which are higher than the limiting diffusion rate constant of this biomolecule ($2 \times 10^{10} \text{ M}^{-1} \text{ s}^{-1}$).⁹⁸




Fig. 6 Fluorescence emission spectra of EthBr-ct-DNA adduct solution in the absence and presence of an increasing amount of silver(i) complex 4. The arrow shows the fluorescence intensity changes upon increased concentrations of the complex. Inserted graph: Stern–Volmer plots of F_0/F vs. $[\text{complex}]$.

Catalytic activity of copper(II) complexes 1 and 2

Mimicking the oxidase catalytic activity of the presently synthesized copper(II) complexes 1 and 2 represents also the aim of this study. Hence, two copper(II)-containing enzymes, catechol oxidase (CAO) and phenoxazinone synthase (PHS) were chosen for this purpose. These two enzymes catalyze the aerobic oxidation of a wide range of biologically significant phenolic derivatives.¹⁰⁹ The schematic presentation of the reactions catalyzed by these two oxidases is shown in Scheme S1.† Catechol oxidase enzyme belongs to the type-3 copper proteins characterized by a dinuclear copper active site which is EPR silent in the native met $\text{Cu}^{\text{II}}\text{-Cu}^{\text{II}}$ form, due to a strong anti-ferromagnetic coupling between the $\mu\text{-OH}$ -bridged $\text{Cu}(\text{II})$ ions.^{110,111} This enzyme catalyzes the oxidation of catechols to the corresponding quinones, that undergo auto polymerization process, leading to the formation of the brown pigment melanin, which is responsible for protection of damaged tissues against pathogens.¹¹² Furthermore, one of the major multi-copper oxidase enzyme, which belongs to the type-2 copper proteins is phenoxazinone synthase, which is found naturally in the bacterium *Streptomyces antibioticus*.^{113,114} This enzyme catalyzes the oxidative coupling of *o*-aminophenols, resulting in the production of the phenoxazinone chromophore in the final stage of the biosynthesis of actinomycin D, which is a naturally occurring antitumor agent.¹¹⁵ The synthesis and investigation of functional model transition metal complexes for metalloenzymes that mimic the oxidase activity is therefore of profound importance for the development of new and efficient bioinspired catalysts for different oxidation reactions. This study helps not only to understand the biochemical phenomena in the natural systems but also clues to the development of small molecule catalysts for specific oxidation reaction under mild conditions.¹¹⁶ In the light of the abovementioned facts, various dinuclear as well as mononuclear copper(II) complexes have been recently shown as successful models for both catechol oxidase and phenoxazinone synthase metalloenzymes.^{116–118}

In order to investigate the catalytic activity of the copper(II) complexes 1 and 2 for CAO activity, 3,5-di-*tert*-butylcatechol (3,5-DTBC) was used as a substrate. This substrate has the bulky groups, which prevent ring opening and shows an increase in the absorbance at 400.0 nm, because of the formation of 3,5-di-*tert*-butylquinone (3,5-DTBQ).¹¹⁹ The catalytic activity of the synthesized complexes was investigated by following the oxidation of 3,5-DTBC to 3,5-DTBQ by mixing the methanolic solution of the substrate and the solution of the corresponding complex in DMSO/methanol (v/v 1 : 9) under aerobic conditions

Table 4 Values of the binding constants of copper(II) (1 and 2) and silver(i) (3 and 4) complexes with ct-DNA

Complex	$K_{\text{SV}} (\text{M}^{-1})$	Hypochromism (%)	$K_q (\text{M}^{-1} \text{ s}^{-1})$	$K_A (\text{M}^{-1})$	n
1	$(1.67 \pm 0.01) \times 10^3$	28.2	1.67×10^{11}	3.67×10^2	0.80
2	$(2.63 \pm 0.01) \times 10^2$	5.4	2.63×10^{10}	4.22×10^1	0.50
3	$(1.50 \pm 0.01) \times 10^3$	17.9	1.50×10^{11}	1.37×10^3	0.99
4	$(1.14 \pm 0.01) \times 10^3$	15.4	1.14×10^{11}	2.00×10^3	1.06






Fig. 7 UV-Vis spectral changes recorded for the reactions of copper(II) complex 2 (1.0 mM, dissolved in DMSO/methanol (v/v 1 : 9)) with an increasing concentration (0–165 μM) of 3,5-DTBC (A) and OAP (B) in methanol at room temperature. Arrow shows the change of absorbance intensity upon an increasing concentration of the substrates.

at room temperature by UV-Vis spectrophotometry. As can be seen from Fig. 7A for complex 2, a gradual increase in absorbance at 400.0 nm is in accordance with significant oxidase activity for the oxidation of 3,5-DTBC to 3,5-DTBQ.

A similar experiment was performed to examine the catalytic activity of the complexes 1 and 2 for PHS activity, *i.e.* in the process of the catalytic oxidation of *o*-aminophenol (OAP) to 2-aminophenoxazine-3-one (APX). An increase in the absorbance at 435.0 nm, was observed in the UV-Vis spectra for both complexes, confirming the conversion of OAP to APX and their catalytic activity (Fig. 7B).¹¹⁹ It is also important to note that the reference experiment in the absence of copper(II) catalyst was performed under the investigated reaction conditions, and the amount of the oxidized products 3,5-DTBQ and APX can be neglected in comparison to that formed in the presence of complexes 1 and 2.

Experimental

Materials and instrumentation

Copper(II) salts ($\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ and $\text{Cu}(\text{CF}_3\text{SO}_3)_2$), silver(I) salts (AgPF_6 and AgNO_3), silver(I) sulfadiazine (AgSD), ethanol, methanol, acetone, dimethyl sulfoxide (DMSO), deuterated DMSO, phosphate buffered saline (PBS), bovine serum albumin (BSA), calf thymus DNA (ct-DNA), ethidium bromide (EthBr), *n*-octanol, 3,5-di-*tert*-butylcatechol (3,5-DTBC) and *o*-aminophenol (OAP) were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). All chemicals (reagents and solvents) were used as supplied without purification.

Elemental microanalysis for carbon, hydrogen and nitrogen of the synthesized copper(II) and silver(I) complexes was performed by the Microanalytical Laboratory, Faculty of Chemistry, University of Belgrade. The IR spectra in the 4000–450 cm^{-1} region were recorded using PerkinElmer Spectrum 100 spectrometer by KBr pellet technique (abbreviations used: vs for very strong, s for strong, m for medium, w for weak). ^1H NMR spectra for py-2pz and silver(I) complexes 3 and 4 were recorded on a Bruker Avance III spectrometer at 500 MHz at room temperature using tetramethylsilane as the internal standard. 5.0 mg of each compound was dissolved in 0.6 mL of DMSO-d_6 and transferred into a 5 mm NMR tube. Chemical shifts (δ) are expressed in ppm and coupling constants (J) are given in Hz. The UV-Vis spectra were recorded on a Shimadzu double-beam spectrophotometer after dissolving the copper(II) and silver(I) complexes in DMSO, as well as after 48 h standing at ambient temperature, over the wavelength range of 1100–200 nm. The concentrations of the solutions used for these measurements were 1×10^{-2} M (1 and 2), 2.63×10^{-5} M (3) and 5.21×10^{-5} M (4). Moreover, the solution behavior of complexes 1–4 was studied by UV-Vis measurements in DMSO/PBS (v/v is 2 : 1 for 1 and 2, 1 : 42.9 for 3 and 1 : 23.1 for 4) over 48 h at room temperature. Molar conductivity measurements were measured at room temperature on a digital conductivity-meter Crison Multimeter MM 41. The concentration of the solutions of complexes in DMSO used for these measurements was 1×10^{-3} M. The cyclic voltammetry (CV) measurements were performed using a potentiostat/galvanostat AutoLab PGSTAT204. The cell (5.0 mL) consisted of three electrode system, glassy carbon (GC) electrode as a working electrode, Ag/AgCl (saturated KCl) as a reference electrode and platinum wire as a counter electrode. All reported potentials are referred *versus* the Ag/AgCl (saturated KCl) reference electrode. The fluorescence emission spectra for DNA/BSA interactions of the complexes were recorded using Jasco FP-6600 spectrophotometer.

Synthesis of dimethyl 6-(pyrazine-2-yl)pyridine-3,4-dicarboxylate

Dimethyl 6-(pyrazine-2-yl)pyridine-3,4-dicarboxylate (py-2pz) used for the synthesis of copper(II) and silver(I) complexes were prepared by the method previously described in the literature.⁴¹ The purity of the synthesized compound was confirmed by elemental microanalysis and ^1H NMR spectroscopy.

Synthesis of complexes 1–4

Copper(II) complexes, $[\text{CuCl}_2(\text{py-2pz})]_2$ (1) and $[\text{Cu}(\text{CF}_3\text{SO}_3)(\text{H}_2\text{O})(\text{py-2pz})_2]\text{CF}_3\text{SO}_3 \cdot 2\text{H}_2\text{O}$ (2), and silver(I) complexes $[\text{Ag}(\text{py-2pz})_2]\text{PF}_6$ (3) and $[\{\text{Ag}(\text{NO}_3)(\text{py-2pz})\} \cdot 0.5\text{H}_2\text{O}]_n$ (4) were synthesized according to the modified procedures for the preparation of copper(II) and silver(I) complexes with pyridine-4,5-dicarboxylate esters as ligands.^{24,37}

The solution of 1.0 mmol of py-2pz (273.2 mg) in 10.0 mL of ethanol was added slowly under stirring to the solution containing an equimolar amount of the corresponding metal salt (170.5 mg of $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ for 1, 361.7 mg of $\text{Cu}(\text{CF}_3\text{SO}_3)_2$ for 2,



252.8 mg of AgPF₆ for **3** and 169.8 mg of AgNO₃ for **4**) in 5.0 mL of ethanol. The reaction mixture was stirred for 3 h on a magnetic stirrer at room temperature (in dark for **3** and **4**). Complexes **1** and **3** were obtained after recrystallization of obtained solid products in a mixture of methanol and water (v/v 1 : 1) and acetone, respectively, while complexes **2** and **4** crystallized from the mother ethanol solution after evaporation at room temperature for 3–5 days. The crystals suitable for single crystal X-ray diffraction analysis were filtered off and dried on room temperature. Yield (calculated on the basis of py-2pz): 256.8 mg (63%) for **1**, 283.9 mg (59%) for **2**, 283.8 mg (71%) for **3** and 252.6 mg (57%) for **4**.

Anal. calcd for **1** = C₂₆H₂₂Cl₄Cu₂N₆O₈ (MW = 815.37): C, 38.30; H, 2.72; N, 10.31. Found: C, 38.17; H, 2.77; N, 10.46%. IR (KBr, ν , cm⁻¹): 3085w, 3049w (ν (C_{ar}-H)), 2956w (ν (C-H)), 1749vs, 1726vs (ν (C=O)), 1615w, 1556m, 1438m, 1429m, 1410m, 1385m (ν _{as}(C_{ar}=C_{ar}) and ν _{as}(C_{ar}=N)), 1306vs, 1281vs, 1270vs (ν (C-O)), 795m (γ (C_{ar}-H)). UV-Vis (DMSO, λ_{max} , nm): 875.0 (ϵ = 1.02 × 10² M⁻¹ cm⁻¹). Λ_{M} (DMSO): 27.4 Ω^{-1} cm² mol⁻¹.

Anal. calcd for **2** = C₂₈H₂₈CuF₆N₆O₁₇S₂ (MW = 962.22): C, 34.95; H, 2.93; N, 8.73. Found: C, 34.78; H, 3.01; N, 8.82%. IR (KBr, ν , cm⁻¹): 3475br (ν (O-H)), 3115w, 3093w, 3059w (ν (C_{ar}-H)), 2959w, 2932w (ν (C-H)), 1730vs (ν (C=O)), 1647w, 1618m, 1592w, 1560m, 1536w, 1497w, 1489w, 1440m, 1416m, 1390m (ν _{as}(C_{ar}=C_{ar}) and ν _{as}(C_{ar}=N)), 1315s (ν (C-O)), 1285vs, 1255vs (ν _{as}(SO₃)), 1226s (ν _s(CF₃)), 1163s, 1107m (ν _{as}(CF₃)), 1084w, 1052m, 1030s (ν _s(SO₃)), 797m (γ (C_{ar}-H)). UV-Vis (DMSO, λ_{max} , nm): 805.0 (ϵ = 43.8 M⁻¹ cm⁻¹). Λ_{M} (DMSO): 84.1 Ω^{-1} cm² mol⁻¹.

Anal. calcd for **3** = C₂₆H₂₂AgN₆F₆O₈P (MW = 799.33): C, 39.07; H, 2.77; N, 10.51. Found: C, 39.25; H, 2.72; N, 10.58%. IR (KBr, ν , cm⁻¹): 3109w (ν (C_{ar}-H)), 2963w, 2932w (ν (C-H)), 1733vs (ν (C=O)), 1607m, 1562w, 1552w, 1489w, 1441m, 1412w, 1375w (ν _{as}(C_{ar}=C_{ar}) and ν _{as}(C_{ar}=N)), 1314s, 1301s, 1279s, 1250m (ν (C-O)), 839vs (ν (P-F)), 796m (γ (C_{ar}-H)). ¹H NMR (500 MHz, DMSO-d₆): δ = 3.92 (d, J = 6.1 Hz, 6H, Ar-COOCH₃), 8.58 (d, J = 0.6 Hz, 1H, H5), 8.84 (m, 2H, H5' and H6'), 9.17 (d, J = 0.7 Hz, 1H, H2), 9.60 (d, J = 0.9 Hz, 1H, H3') ppm. UV-Vis (DMSO, λ_{max} , nm): 296.0 (ϵ = 3.3 × 10⁴ M⁻¹ cm⁻¹). Λ_{M} (DMSO): 30.9 Ω^{-1} cm² mol⁻¹.

Anal. calcd for **4** = C₁₃H₁₂AgN₄O_{7.5} (MW = 452.14): C, 34.53; H, 2.68; N, 12.39. Found: C, 34.72; H, 2.58; N, 12.46%. IR (KBr, ν , cm⁻¹): 3072w, 3034w, 3009w (ν (C_{ar}-H)), 2957m, 2929m (ν (C-H)), 1733vs, 1720vs (ν (C=O)), 1660w, 1636w, 1623w, 1598m, 1556m, 1439m (ν _{as}(C_{ar}=C_{ar}) and ν _{as}(C_{ar}=N)), 1384s, 1368s (ν _{as}(NO₃)), 1332s, 1315m, 1291vs, 1280vs, 1263s (ν (C-O)), 798m (γ (C_{ar}-H)). ¹H NMR (500 MHz, DMSO-d₆): δ = 3.92 (d, J = 6.1 Hz, 6H, Ar-COOCH₃), 8.58 (d, J = 0.6 Hz, 1H, H5), 8.84 (s, 2H, H5' and H6'), 9.18 (d, J = 0.6 Hz, 1H, H2), 9.60 (d, J = 2.6 Hz, 1H, H3') ppm. UV-Vis (DMSO, λ_{max} , nm): 296.0 (ϵ = 1.6 × 10⁴ M⁻¹ cm⁻¹). Λ_{M} (DMSO): 37.6 Ω^{-1} cm² mol⁻¹.

Crystallographic data collection and refinement of the structures

X-ray diffraction data was collected on an Oxford Diffraction SuperNova diffractometer with Mo/Cu microfocus X-ray source with mirror optics and an Atlas detector at 150(2) K. The

structures were solved in Olex2 graphical user interface⁴³ by direct methods implemented in SHELXT and refined by a full-matrix least-squares procedure based on F² using SHELXL.¹²⁰ All non-hydrogen atoms were refined anisotropically. The hydrogen atoms were placed at calculated positions and treated using appropriate riding models. Additional details on structural properties and refinement details are given in the ESI (Tables S2 and S3†).

Computational details

All DFT calculations have been performed with the ADF^{121,122} engine in Amsterdam Modeling Suite (version 2022.102).¹²³ The all-electron triple-zeta Slater-type orbitals plus one polarization function (TZP) basis set was used for all atoms. Relativistic effects were accounted for by the scalar-relativistic Zeroth-Order Regular Approximation (ZORA).^{124–126} Open-shell copper(II) complexes **1** and **2** are treated with unrestricted DFT formalism. Geometry optimizations with the Quasi-Newton method and delocalized coordinates¹²⁷ were performed using general gradient approximation consisting of Becke's exchange¹²⁸ and Perdew's correlation¹²⁹ with Grimme's fourth generation dispersion energy corrections,¹³⁰ *i.e.* BP86-D4 density functional. The COSMO solvation model,^{131,132} as implemented in ADF,¹³³ with DMSO as solvent was used. Analytical harmonic frequencies^{134–136} were calculated at the same level of theory. Vibrational analysis with free rotor interpolation corrections as proposed by Grimme¹³⁷ for low-frequency contributions (frequency cut-off 100 cm⁻¹) has been used to evaluate zero-point and entropic effects to the Gibbs free energy at 298 K. Because vibrational analysis is done at a standard state of 1 atm, conversion to 1 mol dm⁻³ solution standard state is done (correction of 1.89 kcal mol⁻¹ to the free energies at 298 K). Electronic energies used to calculate the Gibbs free energy were evaluated with M06-2X^{138,139} meta-hybrid functional at ZORA-BP86-D4/TZP-COSMO (DMSO) geometries. The exchange coupling constant J in complex **1** was calculated with broken-symmetry DFT formalism^{140–144} at ZORA-M06-2X/TZP level of theory at X-ray geometry according to the Yamaguchi approach.¹⁴⁵ Broken symmetry solutions are obtained from the high-spin states with the spin-flip method. Before single-point calculations on the dinuclear Cu(II) complex from the X-ray structure, the positions of hydrogen atoms were optimized at the ZORA-BP86-D4/DZP level of theory. The Fast Inertial Relaxation Engine¹⁴⁶ based optimizer in Cartesian coordinates was used for hydrogen optimization. The LibXC library¹⁴⁷ was used for all calculations employing M06-2X functional. The Cartesian coordinates of all the optimized structures are available in the ESI.†

Evaluation of antimicrobial potential of complexes 1–4

For determination of minimal inhibitory concentration (MIC) values of complexes **1–4**, standardized broth microdilution methodology was used, recommended by the National Committee for Clinical Laboratory Standards (M07-A8) for bacteria and Standards of European Committee on Antimicrobial Susceptibility Testing (v 7.3.1: method for the



determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts) for *Candida* spp.¹⁴⁸ In this study, two bacterial strains (*Pseudomonas aeruginosa* NCTC 10332 and *Staphylococcus aureus* ATCC 25923) and two fungal strains (*Candida albicans* ATCC 10231 and *Candida parapsilosis* ATCC 22019) were used (NCTC is National Collection of Type Cultures, ATCC is American Type Culture Collection). All tested compounds were firstly dissolved in DMSO at a concentration of 50 mg mL⁻¹, to reach the highest tested concentration of 500 µg mL⁻¹ (making sure that the final concentration of the DMSO in the assay was lower than 1%, v/v). The inoculums were 5 × 10⁵ colony forming units, cfu mL⁻¹, for bacteria and 1 × 10⁵ cfu mL⁻¹ for fungal species. The positive control was silver(i) sulfadiazine (AgSD) as the most widely used antimicrobial agent based on the silver(i). The MIC value was recorded as the lowest concentration that inhibited the growth after 24 h at 37 °C, using the Tecan Infinite 200 Pro multiplate reader (Tecan Group Ltd, Männedorf, Switzerland).

In vitro toxicity assessment

Antiproliferative activity of complexes 1–4 was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay¹⁴⁹ on human lung fibroblasts cells (MRC-5), obtained from the American Type Culture Collection (ATCC). The inoculums of 1 × 10⁴ cells per well were cultured in the complete RPMI 1640 medium (RPMI is Roswell Park Memorial Institute; Gibco™ by Thermo Fischer Scientific, CE) as a monolayer and further incubated with the tested compounds at a concentration from a maximum of 120 µM, in a humidified atmosphere of 95% air and 5% CO₂ at 37 °C for 48 h. The extent of MTT reduction was measured spectrophotometrically at 540.0 nm using Tecan Infinite 200 Pro multiplate reader (Tecan Group Ltd, Männedorf, Switzerland). Cytotoxicity was expressed as the concentration of the tested compound, which inhibits the cell growth by 50% (IC₅₀) in comparison with the negative control (DMSO-treated cells).

Inhibition of *Candida albicans* ATCC 10231 hyphae formation. Complexes 1–4 were further tested for their ability to inhibit *C. albicans* hyphae formation on the solid Spider medium.¹⁵⁰ The medium was poured into 24 well microtiter plate with the addition of subinhibitory concentration of complexes (0.5 × MIC). After solidification, 1.0 µL of *C. albicans* ATCC 10231 overnight culture was placed in the center of the medium. Plate was incubated in upright position on 30 °C for 72 h. Growth was observed and photographed under a stereomicroscope (SMZ143-N2GG, Motic, Germany).

Inhibition of *Candida albicans* ATCC 10231 biofilm formation. The *C. albicans* ATCC 10231 biofilm formation assay was performed using the previously described methodology¹⁵¹ with some minor modifications. Starting inoculum of *C. albicans* for the biofilm inhibition assay was 1 × 10⁶ cfu mL⁻¹ and the concentration gradient of the tested complexes was from 3.5 µg mL⁻¹ with two-fold serial dilutions following up to 0.05 µg mL⁻¹. The lowest concentration that inhibited biofilm formation was evaluated after incubation for 48 h at 37 °C. Biofilm growth was quantified by crystal violet (CV) staining of adherent

cells and estimated as absorbance at 590.0 nm on Tecan Infinite 200 Pro multiplate reader (Tecan Group Ltd, Männedorf, Switzerland). The assay was repeated three times to achieve low standard deviations.

Evaluation of anti-quorum sensing activity of complexes 1–4.

To study the anti-quorum sensing activity of complexes 1–4, biosensor strain *Chromobacterium violaceum* CV026 and wild type strain *Serratia marcescens* were used in this study. The assessment of the violacein production in *C. violaceum* CV026 was done according to the previously described methodology.¹⁵² This strain was cultivated in LB growth medium (Luria-Bertani medium; 10.0 g per L tryptone, 5.0 g per L yeast extract, 10.0 g per L NaCl) supplemented with appropriate antibiotic overnight at 30 °C and 180 revolutions per minute (rpm) on a rotary shaker. Into semi-solid LB agar (0.3%, w/v, 5.0 mL), 50.0 µL of an overnight culture of *C. violaceum* CV026 supplemented with *N*-hexanoyl-L-homoserine lactone (Sigma, Germany) to a final concentration of 5.0 µM was seeded and finally poured over the surface of LB agar plates. *N*-hexanoyl-L-homoserine lactone was used because this biosensor strain is not capable to produce autoinducer for quorum sensing signaling pathway and for this assay it is added externally. After solidification, the sterile discs were placed into the surface of plates and complexes were added in appropriate concentrations (500 and 250 µg per disc). Petri dishes were incubated at 30 °C in upright position overnight.

Serratia marcescens ATCC 27117 was used for the assessment of influence of complexes 1–4 on prodigiosin production. The methodology was the same as for the *C. violaceum* CV026 assay, but no autoinducer was needed.¹⁵³

Inhibition of violacein and prodigiosin production was defined as the presence of blurry white hallos around discs containing compound, measured in mm and it was distinguished from the zones of clearance that indicated growth inhibition of the tested strains.

DNA binding study

Sample preparation. The complexes 1–4 were dissolved in DMSO (10 mM). A stock solution of ct-DNA was prepared by dissolving the solid substance in PBS. The concentration of the obtained ct-DNA solution was determined from UV absorbance at 260.0 nm using the molar extinction coefficient $\epsilon = 6.6 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$.¹⁵⁴ A stock solution of ethidium bromide (EthBr) was prepared fresh in DMSO (1.18 × 10⁻² M) and kept at 4 °C prior to use.

Fluorescence emission spectroscopy. A competitive study with EthBr as an intercalating marker was performed by fluorescence emission spectroscopy to study the DNA binding affinity of the complex. These studies were carried out in PBS (pH 7.4) by maintaining [DNA]/[EthBr] = 10, while increasing the concentration of the complexes. Each sample solution was scanned in the wavelength range of 550.0–750.0 nm with an excitation wavelength of 545.0 nm. The Stern–Volmer constants (K_{sv}) were calculated according to the Stern–Volmer equation:⁹⁷



$$F_0/F = 1 + K_q \tau_0 [\text{complex}] = 1 + K_{sv} [\text{complex}]$$

where F_0 and F are the fluorescence emission intensities of EthBr–DNA in the absence and presence of the quencher, K_q stands for the bimolecular quenching constant and τ_0 (10^{-8} s) is the average fluorescence lifetime of the fluorophore in the absence of the quencher. The binding constants and apparent binding sites were calculated using the following equation:¹⁵⁵

$$\log(F_0 - F)/F = \log K_A + n \log[\text{complex}]$$

where K_A stands for the binding constant of the copper(II) complex with ct-DNA, and n represents the apparent number of binding sites per DNA molecule.

Protein binding study

The protein binding study was performed by tryptophan fluorescence quenching experiments using BSA (5 μM) in PBS (pH 7.4). The quenching of the emission intensity of tryptophan residues of BSA at 365.0 nm was monitored using the increasing concentration of the complexes 1–4 (up to 130 μM). Fluorescence spectra were recorded in the range 295.0–500.0 nm with an excitation wavelength of 290.0 nm. The corresponding binding constants of the complexes (K_A) and apparent binding sites (n) were calculated as it was explained for DNA binding study.^{97,155}

Lipophilicity assay

The lipophilicity of the complexes was determined by the flask-shaking method.¹⁰⁰ The complexes 1–4 were dissolved in DMSO and added to water/*n*-octanol system. This mixture was vortexed for 1 h at 25 °C to allow partitioning. After that time, the solutions were left to stand for 24 h until the separation of two phases. The concentration of complexes in both phases was determined by measuring absorbance values using previously determined calibration curves. Log P values were calculated according to the following equation:

$$\log P = \log(c_o/c_w)$$

where c_o is the concentrations of *n*-octanol and c_w is the concentrations of water phase.

Catalytic activity of copper(II) complexes 1 and 2

3,5-Di-*tert*-butylcatechol (3,5-DTBC) and *o*-aminophenol (OAP) were used as substrates for investigation of the oxidase biomimetic catalytic activity of copper(II) complexes 1 and 2 (Scheme S1†). The solutions of 3,5-DTBC and OAP were prepared in DMSO, while complexes were dissolved in DMSO/water (v/v 1 : 9). The progress of the reaction was followed by UV-Vis spectrophotometry by monitoring the increase of the absorbance of the quinone band at 400.0 nm ($\epsilon = 1.9 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$)¹⁵⁶ and amino phenoxazinone at 435.0 nm ($\epsilon = 9.095 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$)¹⁵⁷ as a function of time.

Conclusions

In the present study, synthesis, structural characterization and biological evaluation of four new copper(II) and silver(I) complexes with dimethyl 6-(pyrazine-2-yl)pyridine-3,4-dicarboxylate (py-2pz), $[\text{CuCl}_2(\text{py-2pz})_2]$ (1), $[\text{Cu}(\text{CF}_3\text{SO}_3)(\text{H}_2\text{O})(\text{py-2pz})_2]\text{CF}_3\text{SO}_3 \cdot 2\text{H}_2\text{O}$ (2), $[\text{Ag}(\text{py-2pz})_2]\text{PF}_6$ (3) and $\{[\text{Ag}(\text{NO}_3)(\text{py-2pz})] \cdot 0.5\text{H}_2\text{O}\}_n$ (4) have been reported. The obtained spectroscopic and crystallographic results have shown that py-2pz ligand is bidentately coordinated to the Cu(II) and Ag(I) ions through its pyridine and pyrazine nitrogen atoms in all complexes, while in polynuclear complex 4, heterocyclic pyrazine ring of py-2pz additionally acts as a bridging ligand between two Ag(I) ions. According to the DFT results, studied copper(II) and silver(I) complexes in DMSO solution are most stable as tetra-coordinated species. Furthermore, DFT calculations revealed a weak ferromagnetic coupling between Cu(II) centers in the X-ray structure of dinuclear complex 1. Silver(I) complexes 3 and 4 have manifested a remarkable antifungal activity on both tested *Candida* strains with MIC values of 4.9 and 8.6 μM (3.9 $\mu\text{g mL}^{-1}$), respectively, while no significant anti-*Candida* activity was observed for copper(II) complexes 1 and 2 (MIC values are higher than 500 μM). Moreover, the complexes 3 and 4 have shown a good antibacterial activity against *P. aeruginosa* PAO1 with MIC being 19.5 and 8.6 μM (15.6 and 3.9 $\mu\text{g mL}^{-1}$, respectively), while the activity of 1 and 2 against this strain is moderate (MIC = 153.3 and 259.8 μM ; 125 and 250 $\mu\text{g mL}^{-1}$, respectively). The significantly higher antimicrobial potential of the synthesized silver(I) complexes can be attributed to the presence of Ag(I) ion, which can show its activity through different pathways, including the interactions with proteins, enzymes and DNA, as well as the ROS production. All synthesized complexes had the ability to inhibit the hyphae formation of *C. albicans*, while silver(I) complexes 3 and 4 also have shown the activity towards biofilms of this fungus. The complexes 1–4 can bind to the serum albumin tightly and reversibly (K_A are in the range 2.15×10^4 to $6.03 \times 10^6 \text{ M}^{-1}$), while the interaction with DNA is rather electrostatic since their K_A values are much lower than that for EthBr and that the percentage of hypochromism is less than 30%. Finally, two copper(II) complexes 1 and 2 have been shown as successful models for both copper(II)-containing metalloenzymes, catechol oxidase and phenoxazinone synthase.

Overall, the obtained results confirm that the nature of metal ion coordinated to the planar organic molecule has a significant influence on the antimicrobial activity of the resulted metal complex. Thus, the coordination of the organic molecule (py-2pz) to the Ag(I) ion leads to the formation of significantly more active complexes against the microbial strains in respect to its coordination to Cu(II), what is in accordance with current use of silver and its compounds in medicine for treatment of various microbial infections. The latter finding along with those previously reported for the structurally similar ligands, such as derivatives of pyridine-4,5-dicarboxylate esters, should be taken into consideration in design of novel metal-based compounds for potential use in medicine.



Author contributions

Conceptualization, T. P. A., I. T., M. I. Dj. and B. Đ. G.; methodology, T. P. A., I. A., J. K., M. P. and S. V.; software, J. K., M. P. and M. Z.; validation, J. N. R., I. T., M. I. Dj. and B. Đ. G.; investigation, T. P. A., I. A., J. K., M. P., M. Z. and S. V.; resources, I. T. and M. I. Dj.; writing-original draft preparation, T. P. A., I. A., J. K., M. P., M. Z. and S. V.; writing-review and editing, J. N. R., I. T., M. I. Dj. and B. Đ. G.; visualization, T. P. A., I. A., J. K., M. P., M. Z. and S. V.; supervision, I. T., M. I. Dj. and B. Đ. G. All authors read and approved the final manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

This research has been financially supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia (Agreements No. 451-03-68/2022-14/200026, 451-03-68/2022-14/200042 and 451-03-68/2022-14/200122) and by the Slovenian Research Agency (grant P1-0175). The EN→FIST Centre of Excellence, Trg OF 13, SI-1000 Ljubljana, Slovenia, is acknowledged for the use of the SuperNova diffractometer. This research has also received funding from the Serbian Academy of Sciences and Arts under project No. F128. MZ acknowledges the support of the Science Fund of the Republic of Serbia for the computational part of this work (project #7750288, Tailoring Molecular Magnets and Catalysts Based on Transition Metal Complexes – TMMagCat).

Notes and references

- 1 S. Nasiri Sovari and F. Zobi, *Chemistry*, 2020, **2**, 418–452.
- 2 M. Gajdács, E. Urbán, A. Stájer and Z. Baráth, *Eur. J. Investig. Health Psychol. Educ.*, 2021, **11**, 71–82.
- 3 J. O'Neill, *Review on Antimicrobial Resistance Antimicrobial Resistance: tackling a crisis for the health and wealth of nations*, London: Review on Antimicrobial Resistance, 2014.
- 4 M. E. A. de Kraker, A. J. Stewardson and S. Harbarth, *PLoS Med.*, 2016, **13**, e1002184.
- 5 F. Prestinaci, P. Pezzotti and A. Pantosti, *Pathog. Global Health*, 2015, **109**, 309–318.
- 6 C. J. L. Murray, K. S. Ikuta, F. Sharara, L. Swetschinski, G. R. Aguilar, A. Gray, C. Han, C. Bisignano, P. Rao, E. Wool, S. C. Johnson, A. J. Browne, M. G. Chipeta, F. Fell, S. Hackett, G. Haines-Woodhouse, B. H. K. Hamadani, E. A. P. Kumaran, B. McManigal, S. Achalapong, R. Agarwal, S. Akech, S. Albertson, J. Amuasi, J. Andrews, A. Aravkin, E. Ashley, F.-X. Babin, F. Bailey, S. Baker, B. Basnyat, A. Bekker, R. Bender, J. A. Berkley, A. Bethou, J. Bielicki, S. Boonkasidecha, J. Bukosia, C. Carvalheiro, C. Castañeda-Orjuela, V. Chansamouth, S. Chaurasia, S. Chiurchiù, F. Chowdhury, R. C. Donatien, A. J. Cook, B. Cooper, T. R. Cressey, E. Criollo-Mora, M. Cunningham, S. Darboe, N. P. J. Day, M. De Luca, K. Dokova, A. Dramowski, S. J. Dunachie, T. D. Bich, T. Eckmanns, D. Eibach, A. Emami, N. Feasey, N. Fisher-Pearson, K. Forrest, C. Garcia, D. Garrett, P. Gastmeier, A. Z. Giref, R. C. Greer, V. Gupta, S. Haller, A. Haselbeck, S. I. Hay, M. Holm, S. Hopkins, Y. Hsia, K. C. Iregbu, J. Jacobs, D. Jarovsky, F. Javanmardi, M. Khorana, N. Kissoon, E. Kobeissi, T. Kostyanev, K. Phommasone, S. Khuduwan, F. Krapp, R. Krumkamp, A. Kumar, H. H. Kyu, C. Lim, K. Lim, D. Limmathurotsakul, M. J. Loftus, M. Lunn, J. Ma, A. Manoharan, F. Marks, J. May, M. Mayxay, N. Mturi, T. Munera-Huertas, P. Musicha, L. A. Musila, M. M. Mussi-Pinhata, R. N. Naidu, T. Nakamura, R. Nanavati, S. Nangia, P. Newton, C. Ngoun, A. Novotney, D. Nwakanma, C. W. Obiero, T. J. Ochoa, A. Olivas-Martinez, P. Olliaro, E. Ooko, E. Ortiz-Brizuela, P. Ounchanum, G. D. Pak, J. L. Paredes, A. Y. Peleg, C. Perrone, T. Phe, N. Plakkal, A. Ponce-de-Leon, M. Raad, T. Ramdin, S. Rattanavong, A. Riddell, T. Roberts, J. V. Robotham, A. Roca, V. D. Rosenthal, K. E. Rudd, N. Russell, H. S. Sader, W. Saengchan, J. Schnall, J. A. G. Scott, S. Seekaew, M. Sharland, M. Shivamallappa, J. Sifuentes-Osornio, A. J. Simpson, N. Steenkeste, A. J. Stewardson, T. Stoeva, N. Tasak, A. Thaiprakong, G. Thwaites, C. Tigoi, C. Turner, P. Turner, H. R. van Doorn, S. Velaphi, A. Vongpradith, M. Vongsouvath, H. Vu, T. Walsh, J. L. Walson, S. Waner, T. Wangrangsimakul, P. Wannapinij, T. Wozniak, T. E. M. W. Young-Sharma, K. C. Yu, P. Zheng, B. Sartorius, A. D. Lopez, A. Stergachis, C. Moore, C. Dolecek and M. Naghavi, *Lancet*, 2022, **399**, 629–655.
- 7 A. Frei, *Antibiotics*, 2020, **9**, 90.
- 8 A. Frei, J. Zuegg, A. G. Elliott, M. Baker, S. Braese, C. Brown, F. Chen, C. G. Dowson, G. Dujardin, N. Jung, A. P. King, A. M. Mansour, M. Massi, J. Moat, H. A. Mohamed, A. K. Renfrew, P. J. Rutledge, P. J. Sadler, M. H. Todd, C. E. Willans, J. J. Wilson, M. A. Cooper and M. A. T. Blaskovich, *Chem. Sci.*, 2020, **11**, 2627–2639.
- 9 F. Lovering, J. Bikker and C. Humblet, *J. Med. Chem.*, 2009, **52**, 6752–6756.
- 10 F. Lovering, *MedChemComm*, 2013, **4**, 515–519.
- 11 A. W. Hung, A. Ramek, Y. Wang, T. Kaya, J. A. Wilson, P. A. Clemons and D. W. Young, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 6799–6804.
- 12 W. H. B. Sauer and M. K. Schwarz, *J. Chem. Inf. Comput. Sci.*, 2003, **43**, 987–1003.
- 13 W. R. J. D. Galloway, A. Isidro-Llobet and D. R. Spring, *Nat. Commun.*, 2010, **1**, 80.
- 14 C. N. Morrison, K. E. Prosser, R. W. Stokes, A. Cordes, N. Metzler-Nolte and S. M. Cohen, *Chem. Sci.*, 2020, **11**, 1216–1225.
- 15 G. Gasser and N. Metzler-Nolte, *Curr. Opin. Chem. Biol.*, 2012, **16**, 84–91.
- 16 T. Gianferrara, I. Bratsos and E. Alessio, *Dalton Trans.*, 2009, 7588–7598.
- 17 Y. Lin, H. Betts, S. Keller, K. Cariou and G. Gasser, *Chem. Soc. Rev.*, 2021, **50**, 10346–10402.



- 18 P. Chellan and P. J. Sadler, *Chem.–Eur. J.*, 2020, **26**, 8676–8688.
- 19 E. J. Anthony, E. M. Bolitho, H. E. Bridgewater, O. W. L. Carter, J. M. Donnelly, C. Imberti, E. C. Lant, F. Lermyte, R. J. Needham, M. Palau, P. J. Sadler, H. Shi, F.-X. Wang, W.-Y. Zhang and Z. Zhang, *Chem. Sci.*, 2020, **11**, 12888–12917.
- 20 C. Imberti and P. J. Sadler, in *Advances in Inorganic Chemistry*, ed. P. J. Sadler and R. van Eldik, Academic Press, 2020, vol. 75, pp. 3–56.
- 21 M. Kaushal, T. S. Lobana, L. Nim, R. Bala, D. S. Arora, I. Garcia-Santos, C. E. Duff and J. P. Jasinski, *New J. Chem.*, 2019, **43**, 11727–11742.
- 22 S. D. Oladipo, B. Omondi and C. Mocktar, *Polyhedron*, 2019, **170**, 712–722.
- 23 D.-H. Cai, C.-L. Zhang, Q.-Y. Liu, L. He, Y.-J. Liu, Y.-H. Xiong and X.-Y. Le, *Eur. J. Med. Chem.*, 2021, **213**, 113182.
- 24 T. P. Andrejević, I. Aleksic, M. Počkaj, J. Kljun, D. Milivojevic, N. Lj. Stevanović, J. Nikodinovic-Runic, I. Turel, M. I. Djuran and B. Đ. Glišić, *Dalton Trans.*, 2021, **50**, 2627–2638.
- 25 B. Đ. Glišić, I. Aleksic, P. Comba, H. Wadepohl, T. Ilic-Tomic, J. Nikodinovic-Runic and M. I. Djuran, *RSC Adv.*, 2016, **6**, 86695–86709.
- 26 Z. Aziz, S. F. Abu and N. J. Chong, *Burns*, 2012, **38**, 307–318.
- 27 A. Kascatan-Nebioglu, M. J. Panzner, C. A. Tessier, C. L. Cannon and W. J. Youngs, *Coord. Chem. Rev.*, 2007, **251**, 884–895.
- 28 N. A. Johnson, M. R. Southerland and W. J. Youngs, *Molecules*, 2017, **22**, 1263.
- 29 S. Medici, M. Peana, G. Crisponi, V. M. Nurchi, J. I. Lachowicz, M. Remelli and M. A. Zoroddu, *Coord. Chem. Rev.*, 2016, **327–328**, 349–359.
- 30 X. Liang, S. Luan, Z. Yin, M. He, C. He, L. Yin, Y. Zou, Z. Yuan, L. Li, X. Song, C. Lv and W. Zhang, *Eur. J. Med. Chem.*, 2018, **157**, 62–80.
- 31 S. Y. Liao, D. C. Read, W. J. Pugh, J. R. Furr and A. D. Russell, *Lett. Appl. Microbiol.*, 1997, **25**, 279–283.
- 32 C. Chiericatti, J. C. Basílico, M. L. Z. Basílico and J. M. Zamaro, *Microporous Mesoporous Mater.*, 2014, **188**, 118–125.
- 33 M. Claudel, J. V. Schwarte and K. M. Fromm, *Chemistry*, 2020, **2**, 849–899.
- 34 Q. L. Feng, J. Wu, G. Q. Chen, F. Z. Cui, T. N. Kim and J. O. Kim, *J. Biomed. Mater. Res.*, 2000, **52**, 662–668.
- 35 W. K. Jung, H. C. Koo, K. W. Kim, S. Shin, S. H. Kim and Y. H. Park, *Appl. Environ. Microbiol.*, 2008, **74**, 2171–2178.
- 36 H.-J. Park, J. Y. Kim, J. Kim, J.-H. Lee, J.-S. Hahn, M. B. Gu and J. Yoon, *Water Res.*, 2009, **43**, 1027–1032.
- 37 T. P. Andrejević, D. Milivojevic, B. Đ. Glišić, J. Kljun, N. Lj. Stevanović, S. Vojnovic, S. Medic, J. Nikodinovic-Runic, I. Turel and M. I. Djuran, *Dalton Trans.*, 2020, **49**, 6084–6096.
- 38 K. Traven, M. Sinreih, J. Stojan, S. Seršen, J. Kljun, J. Bezenšek, B. Stanovnik, I. Turel and T. L. Rižner, *Chem.-Biol. Interact.*, 2015, **234**, 349–359.
- 39 K. Traven, N. Eleftheriadis, S. Seršen, J. Kljun, J. Bezenšek, B. Stanovnik, I. Turel and F. J. Dekker, *Polyhedron*, 2015, **101**, 306–313.
- 40 T. P. Andrejević, I. Aleksić, J. Kljun, B. V. Pantović, D. Milivojevic, S. Vojnovic, I. Turel, M. I. Djuran and B. Đ. Glišić, *Inorganics*, 2022, **10**, 71.
- 41 J. Bezenšek, B. Prek, U. Grošelj, M. Kasunič, J. Svete and B. Stanovnik, *Tetrahedron*, 2012, **68**, 4719–4731.
- 42 A. W. Addison, T. N. Rao, J. Reedijk, J. van Rijn and G. C. Verschoor, *Dalton Trans.*, 1984, 1349–1356.
- 43 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, *J. Appl. Crystallogr.*, 2009, **42**, 339–341.
- 44 L. Yang, D. R. Powell and R. P. Houser, *Dalton Trans.*, 2007, 955–964.
- 45 N. Lj. Stevanović, T. P. Andrejević, A. Crochet, T. Ilic-Tomic, N. S. Drašković, J. Nikodinovic-Runic, K. M. Fromm, M. I. Djuran and B. Đ. Glišić, *Polyhedron*, 2019, **173**, 114112.
- 46 H. El Hamdani, M. El Amame and C. Duhayon, *J. Mol. Struct.*, 2018, **1155**, 789–796.
- 47 Y. Nakajima, Y. Shiraishi, T. Tsuchimoto and F. Ozawa, *Chem. Commun.*, 2011, **47**, 6332–6334.
- 48 A. S. Potapov, E. A. Nudnova, A. I. Khlebnikov, V. D. Ogorodnikov and T. V. Petrenko, *Inorg. Chem. Commun.*, 2015, **53**, 72–75.
- 49 U. Kalinowska-Lis, A. Felczak, L. Chęcińska, K. Zawadzka, E. Patyna, K. Lisowska and J. Ochocki, *Dalton Trans.*, 2015, **44**, 8178–8189.
- 50 B. J. Hathaway, in *Comprehensive Coordination Chemistry*, ed. G. Wilkinson, R. D. Gillard and J. A. McCleverty, Pergamon, Oxford, 1987, vol. 5.
- 51 Y. Jiang, C.-F. Zhu, Z. Zheng, J.-B. He and Y. Wang, *Inorg. Chim. Acta*, 2016, **451**, 143–147.
- 52 I. Ali, W. A. Wani and K. Saleem, *Synth. React. Inorg. Met.*, 2013, **43**, 1162–1170.
- 53 J. M. S. Cardoso, I. Correia, A. M. Galvão, F. Marques and M. F. N. N. Carvalho, *J. Inorg. Biochem.*, 2017, **166**, 55–63.
- 54 M. Sirajuddin, S. Ali and A. Badshah, *J. Photochem. Photobiol., B*, 2013, **124**, 1–19.
- 55 A. P. Sandoval-Rojas, L. Ibarra, M. T. Cortés, M. A. Macías, L. Suescun and J. Hurtado, *J. Electroanal. Chem.*, 2017, **805**, 60–67.
- 56 E. Franco, E. López-Torres, A. Mendiola and T. Sevilla, *Polyhedron*, 2000, **19**, 441–451.
- 57 J.-Y. Wu, Y.-L. Pan, X.-J. Zhang, T. Sun, Y.-P. Tian, J.-X. Yang and Z.-N. Chen, *Inorg. Chim. Acta*, 2007, **360**, 2083–2091.
- 58 P. Połczyński, R. Jurczakowski and W. Grochala, *J. Phys. Chem. C*, 2013, **117**, 20689–20696.
- 59 D. P. Ašanin, S. Skaro Bogojevic, F. Perdih, T. P. Andrejević, D. Milivojevic, I. Aleksic, J. Nikodinovic-Runic, B. Đ. Glišić, I. Turel and M. I. Djuran, *Molecules*, 2021, **26**, 1871.
- 60 N. Stevanović, M. Zlatar, I. Novaković, A. Pevec, D. Radanović, I. Z. Matić, M. Đorđić Crnogorac, T. Stanojković, M. Vujčić, M. Gruden, D. Sladić, K. Anđelković, I. Turel and B. Čobeljić, *Dalton Trans.*, 2021, **51**, 185–196.



- 61 B. Đ. Glišić, L. Senerovic, P. Comba, H. Wadepohl, A. Veselinovic, D. R. Milivojevic, M. I. Djuran and J. Nikodinovic-Runic, *J. Inorg. Biochem.*, 2016, **155**, 115–128.
- 62 S. Medici, M. Peana, V. M. Nurchi and M. A. Zoroddu, *J. Med. Chem.*, 2019, **62**, 5923–5943.
- 63 T. Bjarnsholt and M. Givskov, *Anal. Bioanal. Chem.*, 2007, **387**, 409–414.
- 64 K. Olejnickova, V. Hola and F. Ruzicka, *Pathog. Dis.*, 2014, **72**, 87–94.
- 65 D. Savoia, *Future Microbiol.*, 2014, **9**, 917–928.
- 66 Z. Vargová, M. Almáši, D. Hudecová, D. Titková, I. Rostašová, V. Zeleňák and K. Györyová, *J. Coord. Chem.*, 2014, **67**, 1002–1021.
- 67 S. H. Alisir, S. Demir, B. Sariboga and O. Buyukgungor, *J. Coord. Chem.*, 2015, **68**, 155–168.
- 68 M. Rendošová, Z. Vargová, D. Sabolová, N. Imrichová, D. Hudecová, R. Gyepes, B. Lakatoš and K. Elefantová, *J. Inorg. Biochem.*, 2018, **186**, 206–216.
- 69 T. Suksrichavalit, S. Prachayasittikul, C. Nantasenammat, C. Isarankura-Na-Ayudhya and V. Prachayasittikul, *Eur. J. Med. Chem.*, 2009, **44**, 3259–3265.
- 70 F. G. da Silva Dantas, A. A. de Almeida-Apolonio, R. P. de Araújo, L. R. V. Favarin, P. F. de Castilho, F. de Oliveira Galvão, T. I. E. Svidzinski, G. A. Casagrande and K. M. P. de Oliveira, *Molecules*, 2018, **23**, 1856.
- 71 C. Santini, M. Pellei, V. Gandin, M. Porchia, F. Tisato and C. Marzano, *Chem. Rev.*, 2014, **114**, 815–862.
- 72 C. N. Banti and S. K. Hadjikakou, *Metallomics*, 2013, **5**, 569–596.
- 73 J. Serment-Guerrero, P. Cano-Sanchez, E. Reyes-Perez, F. Velazquez-Garcia, M. E. Bravo-Gomez and L. Ruiz-Azuara, *Toxicol. In Vitro*, 2011, **25**, 1376–1384.
- 74 R. Galindo-Murillo, J. C. García-Ramos, L. Ruiz-Azuara, T. E. Cheatham III and F. Cortés-Guzmán, *Nucleic Acids Res.*, 2015, **43**, 5364–5376.
- 75 J. Serment-Guerrero, M. E. Bravo-Gomez, E. Lara-Rivera and L. Ruiz-Azuara, *J. Inorg. Biochem.*, 2017, **166**, 68–75.
- 76 J. C. García-Ramos, A. G. Gutiérrez, A. Vázquez-Aguirre, Y. Toledano-Magaña, A. L. Alonso-Sáenz, V. Gómez-Vidales, M. Flores-Alamo, C. Mejía and L. Ruiz-Azuara, *BioMetals*, 2017, **30**, 43–58.
- 77 A. G. Gutiérrez, A. Vázquez-Aguirre, J. C. García-Ramos, M. Flores-Alamo, E. Hernández-Lemus, L. Ruiz-Azuara and C. Mejía, *J. Inorg. Biochem.*, 2013, **126**, 17–25.
- 78 S. Roy, S. Saha, R. Majumdar, R. R. Dighe and A. R. Chakravarty, *Polyhedron*, 2010, **29**, 2787–2794.
- 79 V. M. Manikandamathavan, V. Rajapandian, A. J. Freddy, T. Weyhermüller, V. Subramanian and B. U. Nair, *Eur. J. Med. Chem.*, 2012, **57**, 449–458.
- 80 J. Grau, R. F. Brissos, J. Salinas-Uber, A. B. Caballero, A. Caubet, O. Roubeau, L. Korrodi-Gregório, R. Pérez-Tomás and P. Gamez, *Dalton Trans.*, 2015, **44**, 16061–16072.
- 81 V. M. Manikandamathavan, M. Thangaraj, T. Weyhermüller, R. P. Parameswari, V. Punitha, N. N. Murthy and B. U. Nair, *Eur. J. Med. Chem.*, 2017, **135**, 434–446.
- 82 B. Đ. Glišić, J. Nikodinovic-Runic, T. Ilic-Tomic, H. Wadepohl, A. Veselinović, I. M. Opsenica and M. I. Djuran, *Polyhedron*, 2018, **139**, 313–322.
- 83 J. A. Romo, C. G. Pierce, A. K. Chaturvedi, A. L. Lazzell, S. F. McHardy, S. P. Saville and J. L. Lopez-Ribot, *MBio*, 2017, **8**, e01991.
- 84 N. Božinović, S. Šegan, S. Vojnovic, A. Pavic, B. A. Šolaja, J. Nikodinovic-Runic and I. M. Opsenica, *Chem. Biol. Drug Des.*, 2016, **88**, 795–806.
- 85 N. D. Savić, S. Vojnovic, B. Đ. Glišić, A. Crochet, A. Pavic, G. V. Janjić, M. Pekmezović, I. M. Opsenica, K. M. Fromm, J. Nikodinovic-Runic and M. I. Djuran, *Eur. J. Med. Chem.*, 2018, **156**, 760–773.
- 86 N. Lj. Stevanović, I. Aleksic, J. Kljun, S. Skaro Bogojevic, A. Veselinovic, J. Nikodinovic-Runic, I. Turel, M. I. Djuran and B. Đ. Glišić, *Pharmaceuticals*, 2021, **14**, 24.
- 87 B. S. R. Mohamed, M. Subramanian and K. P. Shunmugiah, *Appl. Microbiol. Biotechnol.*, 2014, **98**, 6775–6785.
- 88 H. T. Taff, K. F. Mitchell, J. A. Edward and D. R. Andes, *Future Microbiol.*, 2013, **8**, 1325–1337.
- 89 F. Imperi, F. Massai, C. R. Pillai, F. Longo, E. Zennaro, G. Rampioni, P. Visca and L. Leoni, *Antimicrob. Agents Chemother.*, 2013, **57**, 996–1005.
- 90 I. M. Stanojević, I. Aleksić, N. S. Drašković, B. Đ. Glišić, S. Vojnović and J. Nikodinović-Runić, *J. Serb. Chem. Soc.*, 2017, **82**, 1357–1367.
- 91 A. Mohanty, C. H. Tan and B. Cao, *Environ. Sci.: Nano*, 2016, **3**, 351–356.
- 92 B. R. Singh, B. N. Singh, A. Singh, W. Khan, A. H. Naqvi and H. B. Singh, *Sci. Rep.*, 2015, **5**, 13719.
- 93 K. Naik and M. Kowshik, *J. Appl. Microbiol.*, 2014, **117**, 972–983.
- 94 A. M. Merlot, D. S. Kalinowski and D. R. Richardson, *Front. Physiol.*, 2014, **5**, 299.
- 95 C. Tan, J. Liu, H. Li, W. Zheng, S. Shi, L. Chen and L. Ji, *J. Inorg. Biochem.*, 2008, **102**, 347–358.
- 96 X. M. He and D. C. Carter, *Nature*, 1992, **358**, 209–215.
- 97 P. Smolénski, C. Pettinari, F. Marchetti, M. F. C. Guedes da Silva, G. Lupidi, G. V. B. Patzmay, D. Petrelli, L. A. Vitali and A. J. L. Pomberio, *Inorg. Chem.*, 2015, **54**, 434–440.
- 98 Y. Shi, C. Guo, Y. Sun, Z. Liu, F. Xu, Y. Zhang, Z. Wen and Z. Li, *Biomacromolecules*, 2011, **12**, 797–803.
- 99 O. H. Laitinen, V. P. Hytönen, H. R. Nordlund and M. S. Kulomaa, *Cell. Mol. Life Sci.*, 2006, **63**, 2992–3017.
- 100 C. A. Puckett and J. K. Barton, *J. Am. Chem. Soc.*, 2007, **129**, 46–47.
- 101 A. Ghezzi, M. Aceto, C. Cassino, E. Gabano and D. Osella, *J. Inorg. Biochem.*, 2004, **98**, 73–78.
- 102 L. Fetzer, B. Boff, M. Ali, M. Xiangjun, J.-P. Collin, C. Sirlin, C. Gaiddon and M. Pfeffer, *Dalton Trans.*, 2011, **40**, 8869–8878.
- 103 A. K. Ghose, V. N. Viswanadhan and J. J. Wendoloski, *J. Comb. Chem.*, 1999, **1**, 55–68.
- 104 C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, *Adv. Drug Delivery Rev.*, 2012, **64**, 4–17.
- 105 S. Neidle, *Therapeutic Applications of Quadruplex Nucleic Acids*, Academic Press, 2012.



- 106 I. Turel and J. Kljun, *Curr. Top. Med. Chem.*, 2011, **11**, 2661–2687.
- 107 J. R. Lakowicz. *Principles of Fluorescence Spectroscopy*, Plenum Press, New York, 3rd edn, 2006.
- 108 H.-L. Wu, W.-Y. Li, X.-W. He, K. Miao and H. Liang, *Anal. Bioanal. Chem.*, 2002, **373**, 163–168.
- 109 J. S. Valentine, C. S. Foote, A. Greenberg and J. F. Liebman, *Active oxygen in biochemistry*, Blackie Academic and Professional, An Imprint of Chapman and Hall, London, 1993.
- 110 S. Torelli, C. Belle, S. Hamman, J.-L. Pierre and E. Saint-Aman, *Inorg. Chem.*, 2002, **41**, 3983–3989.
- 111 C. Gerdemann, C. Eicken and B. Krebs, *Acc. Chem. Res.*, 2002, **35**, 183–191.
- 112 I. A. Koval, P. Gamez, C. Belle, K. Selmeçzi and J. Reedijk, *Chem. Soc. Rev.*, 2006, **35**, 814–840.
- 113 A. W. Smith, A. Camara-Artigas, M. Wang, J. P. Allen and W. A. Francisco, *Biochemistry*, 2006, **45**, 4378–4387.
- 114 C. E. Barry, P. G. Nayar and T. P. Begley, *Biochemistry*, 1989, **28**, 6323–6333.
- 115 X. Mu, L. Song, Q. Li, R. Yin, X. Zhao and D. Wang, *Int. J. Gynecol. Obstet.*, 2018, **143**, 225–231.
- 116 M. Shyamal, T. K. Mandal, A. Panja and A. Saha, *RSC Adv.*, 2014, **4**, 53520–53530.
- 117 A. E.-M. M. Ramadan, S. Y. Shaban, M. M. Ibrahim, S. A. Sallam, F. I. El-Shami and S. Al-Juaid, *J. Mater. Sci.*, 2020, **55**, 6457–6481.
- 118 K. S. Banu, M. Mukherjee, A. Guha, S. Bhattacharya, E. Zangrando and D. Das, *Polyhedron*, 2012, **45**, 245–254.
- 119 N. Ch. Jana, P. Brandão, A. Frontera and A. Panja, *Dalton Trans.*, 2020, **49**, 14216–14230.
- 120 G. M. Sheldrick, *Acta Crystallogr., Sect. A: Found. Adv.*, 2015, **71**, 3–8.
- 121 G. te Velde, F. M. Bickelhaupt, E. J. Baerends, C. Fonseca Guerra, S. J. A. van Gisbergen, J. G. Snijders and T. Ziegler, *J. Comput. Chem.*, 2001, **22**, 931–967.
- 122 E. J. Baerends, T. Ziegler, A. J. Atkins, J. Autschbach, D. Bashford, O. Baseggio, A. Bérces, F. M. Bickelhaupt, C. Bo, P. M. Boerritger, L. Cavallo, C. Daul, D. P. Chong, D. v Chulhai, L. Deng, R. M. Dickson, J. M. Dieterich, D. E. Ellis, M. van Faassen, A. Ghysels, A. Giammona, S. J. A. van Gisbergen, A. Goetz, A. W. Götz, S. Gusarov, F. E. Harris, P. van den Hoek, Z. Hu, C. R. Jacob, H. Jacobsen, L. Jensen, L. Joubert, J. W. Kaminski, G. van Kessel, C. König, F. Kootstra, A. Kovalenko, M. Krykunov, E. van Lenthe, D. A. McCormack, A. Michalak, M. Mitoraj, S. M. Morton, J. Neugebauer, V. P. Nicu, L. Noodleman, V. P. Osinga, S. Patchkovskii, M. Pavanello, C. A. Peeples, P. H. T. Philipsen, D. Post, C. C. Pye, H. Ramanantoanina, P. Ramos, W. Ravenek, J. I. Rodríguez, P. Ros, R. Rüger, P. R. T. Schipper, D. Schlüns, H. van Schoot, G. Schreckenbach, J. S. Seldenthuis, M. Seth, J. G. Snijders, M. Solà, S. M. M. Swart, D. Swerhone, G. te Velde, V. Tognetti, P. Vernooijs, L. Versluis, L. Visscher, O. Visser, F. Wang, T. A. Wesolowski, E. M. van Wezenbeek, G. Wiesenekker, S. K. Wolff, T. K. Woo and A. L. Yakovlev, *ADF 2022.1*, SCM, Theoretical Chemistry, Vrije Universiteit, Amsterdam, The Netherlands, 2022, <https://www.scm.com>.
- 123 R. Rüger, M. Franchini, T. Trnka, A. Yakovlev, E. van Lenthe, P. Philipsen, T. van Vuren, B. Klumpers and T. Soini, *AMS 2022.1*, SCM, Theoretical Chemistry, Vrije Universiteit, Amsterdam, The Netherlands, 2022, <https://www.scm.com>.
- 124 E. van Lenthe, E. J. Baerends and J. G. Snijders, *J. Chem. Phys.*, 1993, **99**, 4597–4610.
- 125 E. van Lenthe, E. J. Baerends and J. G. Snijders, *J. Chem. Phys.*, 1994, **101**, 9783–9792.
- 126 C. van Wüllen, *J. Chem. Phys.*, 1998, **109**, 392–399.
- 127 M. Swart and F. M. Bickelhaupt, *Int. J. Quantum Chem.*, 2006, **106**, 2536–2544.
- 128 A. D. Becke, *Phys. Rev. A*, 1988, **38**, 3098–3100.
- 129 J. P. Perdew, *Phys. Rev. B*, 1986, **33**, 8822–8824.
- 130 E. Caldeweyher, S. Ehlert, A. Hansen, H. Neugebauer, S. Spicher, C. Bannwarth and S. Grimme, *J. Chem. Phys.*, 2019, **150**, 154122.
- 131 A. Klamt and G. Schoermann, *J. Chem. Soc., Perkin Trans. 2*, 1993, 799–805.
- 132 A. Klamt, *J. Phys. Chem.*, 1995, **99**, 2224–2235.
- 133 C. C. Pye and T. Ziegler, *Theor. Chem. Acc.*, 1999, **101**, 396–408.
- 134 A. Bérces, R. M. Dickson, L. Fan, H. Jacobsen, D. Swerhone and T. Ziegler, *Comput. Phys. Commun.*, 1997, **100**, 247–262.
- 135 H. Jacobsen, A. Bérces, D. P. Swerhone and T. Ziegler, *Comput. Phys. Commun.*, 1997, **100**, 263–276.
- 136 S. K. Wolff, *Int. J. Quantum Chem.*, 2005, **104**, 645–659.
- 137 S. Grimme, *Chem.–Eur. J.*, 2012, **18**, 9955–9964.
- 138 Y. Zhao and D. G. Truhlar, *J. Chem. Phys.*, 2006, **125**, 194101.
- 139 Y. Zhao and D. G. Truhlar, *Theor. Chem. Acc.*, 2008, **120**, 215–241.
- 140 G. Jonkers, C. A. de Lange, L. Noodleman and E. J. Baerends, *Mol. Phys.*, 1982, **46**, 609–620.
- 141 L. Noodleman, *J. Chem. Phys.*, 1981, **74**, 5737–5743.
- 142 L. Noodleman and E. R. Davidson, *Chem. Phys.*, 1986, **109**, 131–143.
- 143 L. Noodleman, J. G. Norman, J. H. Osborne, A. Aizman and D. A. Case, *J. Am. Chem. Soc.*, 1985, **107**, 3418–3426.
- 144 F. Neese, *Coord. Chem. Rev.*, 2009, **253**, 526–563.
- 145 T. Soda, Y. Kitagawa, T. Onishi, Y. Takano, Y. Shigeta, H. Nagao, Y. Yoshioka and K. Yamaguchi, *Chem. Phys. Lett.*, 2000, **319**, 223–230.
- 146 E. Bitzek, P. Koskinen, F. Gähler, M. Moseler and P. Gumbsch, *Phys. Rev. Lett.*, 2006, **97**, 170201.
- 147 M. A. L. Marques, M. J. T. Oliveira and T. Burnus, *Comput. Phys. Commun.*, 2012, **183**, 2272–2281.
- 148 M. C. Arendrup, M. Cuenca-Estrella, C. Lass-Flörl and W. Hope, *Clin. Microbiol. Infect.*, 2012, **18**, E246–E247.
- 149 F. Ferrer, R. Fanciullino, G. Milano and J. Ciccolini, *Clin. Pharmacol. Ther.*, 2020, **108**, 458–470.
- 150 H. Liu, J. Köhler and G. R. Fink, *Science*, 1994, **266**, 1723–1726.
- 151 C. G. Pierce, P. Uppuluri, A. R. Tristan, F. L. Wormley Jr, E. Mowat, G. Ramage and J. L. Lopez-Ribot, *Nat. Protoc.*, 2008, **3**, 1494–1500.



- 152 K. H. McClean, M. K. Winson, L. Fish, A. Taylor, S. R. Chhabra, M. Camara, M. Daykin, J. H. Lamb, S. Swift, B. W. Bycroft, G. S. A. B. Stewart and P. Williams, *Microbiology*, 1997, **143**, 3703–3711.
- 153 I. Aleksic, S. Šegan, F. Andrić, M. Zlatović, I. Moric, D. M. Opsenica and L. Senerovic, *ACS Chem. Biol.*, 2017, **12**, 1425–1434.
- 154 R. Bera, B. K. Sahoo, K. S. Ghosh and S. Dasgupta, *Int. J. Biol. Macromol.*, 2008, **42**, 14–21.
- 155 A. Wolfe, G. H. Shimer Jr. and T. Meehan, *Biochem*, 1987, **26**, 6392–6396.
- 156 J. Reim and B. Krebs, *J. Chem. Soc., Dalton Trans.*, 1997, 3793–3804.
- 157 A. C. Sousa, M. C. Oliveira, L. O. Martins and M. P. Robalo, *Green Chem.*, 2014, **16**, 4127–4136.

